6-9 June 2019

Florence Retina Meeting 2019

Florence
Italy

Final Program
## CONTENT

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>WELCOME</td>
<td>4</td>
</tr>
<tr>
<td>COMMITTEES &amp; FACULTY</td>
<td>6</td>
</tr>
<tr>
<td>PROGRAM OVERVIEW</td>
<td>8</td>
</tr>
<tr>
<td>MAIN PROGRAM</td>
<td></td>
</tr>
<tr>
<td>Thursday</td>
<td>10</td>
</tr>
<tr>
<td>Friday</td>
<td>14</td>
</tr>
<tr>
<td>Saturday</td>
<td>25</td>
</tr>
<tr>
<td>Sunday</td>
<td>35</td>
</tr>
<tr>
<td>COURSES</td>
<td></td>
</tr>
<tr>
<td>Nurse Course</td>
<td>38</td>
</tr>
<tr>
<td>AIOOrAO Course</td>
<td>38</td>
</tr>
<tr>
<td>WET LABS</td>
<td>39</td>
</tr>
<tr>
<td>ORAL PRESENTATIONS</td>
<td></td>
</tr>
<tr>
<td>Thursday Presentations - Surgical Session 1</td>
<td>40</td>
</tr>
<tr>
<td>Thursday Presentations - Medical Session 1</td>
<td>42</td>
</tr>
<tr>
<td>Saturday Presentations - Surgical Session 2</td>
<td>45</td>
</tr>
<tr>
<td>Sunday Presentations - Surgical Session 3</td>
<td>47</td>
</tr>
<tr>
<td>Sunday Presentations - Medical Session 2</td>
<td>49</td>
</tr>
<tr>
<td>POSTER PRESENTATIONS</td>
<td>52</td>
</tr>
<tr>
<td>EXHIBITOR LIST AND FLOORPLAN</td>
<td>60</td>
</tr>
<tr>
<td>CONGRESS VENUE FLOORPLANS</td>
<td>62</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>64</td>
</tr>
<tr>
<td>FLORetina APP</td>
<td>70</td>
</tr>
<tr>
<td>ACKNOWLEDGMENTS</td>
<td>71</td>
</tr>
</tbody>
</table>
Dear Friends and Colleagues,

we are pleased to welcome you for the third edition of FLORetina - Florence Retina Meeting.

In 2017, the second edition reached more than 2000 delegates plus corporate, ending up with more than 2600 participants to the event that make FLORetina the biggest retina meeting unrelated to a Society Event. While in the first edition in 2015 the attendance was about 1000 participants, in 2017 the result has doubled. The 2017 program examined all the important issues in both fields of medical and surgical retina. An innovative format for medical and surgical retinologists: separate in the morning, together in the afternoon, and lunch with sponsors.

For this third edition, afternoon Main Sessions will be based on themes of common interest in both medical and surgical retina and focused only on strictly innovative arguments.

**MEDICAL RETINA AND IMAGING**

The Sessions of Medical Retina and Imaging will be full-time on Friday, Saturday and Sunday morning in parallel with surgical sessions. Highly representative opinion leaders will deepen the focus on drugs’ choice and treatment regimen, challenging cases treatment and diagnostic new tools with recent technologies.

**SURGICAL RETINA**

Top Surgeons from all over the world for the first time will be connected through satellite or streaming on the same multiscreen in the Auditorium in Florence together with surgeries held in Careggi Hospital.

We have settled up a FLORetina Surgical International Network - FLORsin with operating rooms in the American,
African and Asian and European continents where international surgeons will perform their surgeries. With the evolution of the surgical procedures, it’s now necessary to specify all the instrumentation used during the surgery. Therefore everything used by the surgeons will be projected on the screen.

**CONSENSUS IN SCIENCE**

The participation of the listed speakers and the presence of experts from all over the world will allow the production of consensus on treatments, treatment strategies and prognostic values of diagnostic techniques. Interactivity will be increased between speakers, moderators and participants through the App that will allow active involvement of the attendees.

*Best Regards,*

*Stanislao Rizzo*

*Francesco Faraldi*

*Carl Claes*

*José García-Arumí*

*Kouroos A. Rezaei*

*Ramin Tadayoni*

*Albert Augustin*

*Ehab EL Rayes*
COMMITEES & FACULTY

ORGANIZERS
Stanislao Rizzo - Florence (Italy)
Francesco Faraldi - Turin (Italy)
Carl Claes - Antwerpen (Belgium)
José García-Arumí - Barcelona (Spain)
Kourous A. Rezaei - Chicago (USA)
Ramin Tadayoni - Paris (France)
Albert Augustin - Karlsruhe (Germany)
Ehab EL Rayes - Cairo (Egypt)

SCIENTIFIC PROGRAM CHAIRS
Tomaso Caporossi - Florence (Italy)
Francesco Barca - Florence (Italy)

SCIENTIFIC SECRETARIAT
Daniela Bacherini - Florence (Italy)
Andrea Giorni - Florence (Italy)
Alfonso Savastano - Florence (Italy)
Dario Mucciolo - Florence (Italy)

SPEAKERS
Massimo Accorinti, ITALY
Rupesh Agrawal, SINGAPORE
Khalid Al Sabti, KUWAIT
Sofia Androudi, GREECE
Martina Angi, ITALY
J. Fernando Arevalo, USA
Paolo Arpa, ITALY
Alessandro Arrigo, ITALY
Albert Augustin, GERMANY
Remzi Avci, TURKEY
Teresio Avitabile, ITALY
Carl C. Awh, USA
Claudio Azzolini, ITALY
Daniela Bacherini, ITALY
Ron Baggage, SWITZERLAND
Emilio Balestrazzi, ITALY
Ernesto Bali, BELGIUM
Francesco Bandello, ITALY
Adiel Barak, ISRAEL
Francesco Barca, ITALY
Maurizio Battaglia Parodi, ITALY
Francine Behar Cohen, SWITZERLAND
Giorgio Beltrame, ITALY
Maria Berrocal, MEXICO
Enrico Bertelli, ITALY
Ilaria Biagini, ITALY
Susanne Binder, AUSTRIA
Enrico Borrelli, ITALY
Francesco Boscia, ITALY
Ferdinando Bottoni, ITALY
Neil Bressler, USA
Susan Bressler, USA
Alexander J Brucker, USA
Jonathan Brugger, USA
Andrea Cacciamani, ITALY
Emilio Campos, ITALY
Antonio Jr. Capone, USA
Tomaso Caporossi, ITALY
Luigi Caretti, ITALY
Matteo Giuseppe Cereda, ITALY
Steve Charles, USA
Paolo Chelini, ITALY
Marzio Chizzolini, ITALY
David Chow, CANADA
Antonio Ciardella, ITALY
Luca Cimino, ITALY
Laura Cinelli, ITALY
Francesca Cipollini, ITALY
Carl Claes, BELGIUM
Rosa M. Coco Martin, SPAIN
Enrica Convento, ITALY
Michele Coppola, ITALY
Borja Corcostegui, SPAIN
Donald J. D’Amico, USA
Lyndon Da Cruz, UNITED KINGDOM
Bertil Damato, UNITED KINGDOM
Romano Danesi, ITALY
Stefano De Gilla, ITALY
Vito De Molfetta, ITALY
Francesca De Rossi, ITALY
Marc De Smet, SWITZERLAND
François Devin, FRANCE
Felipe Dhawahir-Scala, UNITED KINGDOM
Rosa Dolz-March, SPAIN
Dilva Drago, ITALY
Chiara Eandi, ITALY
Claus Eckardt, GERMANY
Ehab EL Rayes, EGYPT
Bruno Falcomatà, ITALY
Benedetto Falsini, ITALY
Francesco Faraldi, ITALY
Koorosh Faridpooya, THE NETHERLANDS
Alessandro Farini, ITALY
Vincenzo Ferrara, ITALY
Philip Ferrone, USA
Marta Figueroa, SPAIN
Lucia Finocchio, ITALY
Tito Fiore, ITALY
Diego Fornasari, ITALY
Iacopo Franchini, ITALY
Thomas Friberg, USA
Jans Fromow, MEXICO
Richard Gale, UNITED KINGDOM
José García-Arumí, SPAIN
Ilias Georgalas, GREECE
Heinrich Gerding, SWITZERLAND
Giovanni Giacomelli, ITALY
Fabrizio Giansanti, ITALY
Giampaolo Gini, ITALY
Matteo Giuntoli, ITALY
Stratos Gotzaridis, GREECE
Giuseppe Guarnaccia, SWITZERLAND
Tarek Hassan, USA
Heinrich Heimann, UNITED KINGDOM
Suber Huang, USA
Ugo Introini, ITALY
Kai Januschowsky, GERMANY
Kristel Jansen, BELGIUM
Mark W. Johnson, USA
Kazuaki Kadono, JAPAN
Judy E. Kim, USA
Adrian Koh, SINGAPORE
Alexey Kulikov, RUSSIA
Vinod Kumar, INDIA
<table>
<thead>
<tr>
<th>Day/Time</th>
<th>Room</th>
<th>Auditorium</th>
<th>Room Verde</th>
<th>Room Onice</th>
<th>Room 9</th>
<th>Room 6</th>
<th>Room 4</th>
<th>Simulation Room</th>
<th>Room 101</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday 6</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td>AUDITORIUM</td>
<td>ADVANCED IMAGING by Yoris</td>
<td>FREE PAPERS</td>
<td>FREE PAPERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td>ROOM VERDE</td>
<td>FOCUS ON OCT-A by SIR</td>
<td>SURGICAL 1</td>
<td>MEDICAL 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td>ROOM ONICE</td>
<td>ESASO: SUBMACULAR TREATMENTS</td>
<td>LIVE SURGERY</td>
<td>INTRAOCULAR TOXICITY COURSE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>ROOM 9</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 17:30</td>
<td>ROOM 6</td>
<td>MYOPIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>ROOM 4</td>
<td>DIABETIC MACULAR EDEMA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30 - 19:00</td>
<td>SIMULATION ROOM</td>
<td>ROOM 101</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Friday 7</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td>AUDITORIUM</td>
<td>LIVE SURGERY</td>
<td>VASCULAR RETINAL DISEASES</td>
<td>INHERITED RETINAL DISEASES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:15 - 09:00</td>
<td>ROOM VERDE</td>
<td></td>
<td>VISION ACADEMY</td>
<td>LOW VISION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>ROOM ONICE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15 - 10:00</td>
<td>ROOM 9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 11:00</td>
<td>ROOM 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>ROOM 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>SIMULATION ROOM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td>ROOM 101</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Friday 7</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td>AUDITORIUM</td>
<td>ALCON Advanced Solution to Enhance the Vitreoretinal Procedure</td>
<td>NOVARTIS It's RIVAL time</td>
<td>NIDEX New Frontiers in Retinal Imaging: OCT Angiography and Multimodal Integrated Evaluation</td>
<td>BAUSCH+LOMB Micronutrients and benefits of supplementation for reducing the risk of retinopathies progression</td>
<td>WET LAB DORC</td>
<td>WET LAB HOYA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:55</td>
<td>ROOM VERDE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:55 - 16:15</td>
<td>ROOM ONICE</td>
<td>FUTURE PERSPECTIVES IN OPHTHALMOLOGY Bausch + Lomb, Bayer, Dorc, Carl Zeiss</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:45</td>
<td>ROOM 9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45 - 17:35</td>
<td>ROOM 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:35 - 18:20</td>
<td>ROOM 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:20 - 19:00</td>
<td>SIMULATION ROOM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day/Time</td>
<td>Room</td>
<td>AUDITORIUM</td>
<td>ROOM VERDE</td>
<td>ROOM ONICE</td>
<td>ROOM 9</td>
<td>ROOM 6</td>
<td>ROOM 4</td>
<td>SIMULATION ROOM</td>
<td>ROOM 101</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>-----------------------------------</td>
<td>---------------------------------</td>
<td>-----------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------------</td>
<td>----------------</td>
<td>----------</td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td></td>
<td>LIVE SURGERY</td>
<td>AMD: NEW DIAGNOSTIC</td>
<td>RETINAL DETACHMENT</td>
<td></td>
<td></td>
<td></td>
<td>DRY LAB</td>
<td>WET LAB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Florence:</td>
<td>AND TREATMENT</td>
<td>ADVANCED COURSE</td>
<td></td>
<td></td>
<td></td>
<td>OFTALMEDICA</td>
<td>HOYA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rizzo S., Patelli F., Bali E.,</td>
<td>STRATEGIES</td>
<td>ENDOPHTHALMITIS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Garcia Arumi J., Caretti L.,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eckardt C., Claes C., Lanzetta P.,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tognetto D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:10</td>
<td></td>
<td>AUDITORIUM</td>
<td>NOVARTIS</td>
<td>SIFI DME patients real</td>
<td>MILOFTALMICA</td>
<td></td>
<td></td>
<td>DRY LAB</td>
<td>WET LAB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fluid control in Wet</td>
<td>life experience with</td>
<td>Adaptive Optics</td>
<td></td>
<td></td>
<td>OFTALMEDICA</td>
<td>HOYA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AMD</td>
<td>Fluocinolone Acetonide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>from both sides of the</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Atlantic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:10 - 10:00</td>
<td></td>
<td>AUDITORIUM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DRY LAB</td>
<td>WET LAB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OFTALMEDICA</td>
<td>HOYA</td>
</tr>
<tr>
<td>10:00 - 11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DRY LAB</td>
<td>WET LAB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OFTALMEDICA</td>
<td>HOYA</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td></td>
<td>HOW DO I DO IT: 3D VIDEO PANEL</td>
<td></td>
<td>FREE PAPERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td></td>
<td>LUNCH</td>
<td></td>
<td>SURGICAL 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DRY LAB</td>
<td>WET LAB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OFTALMEDICA</td>
<td>HOYA</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DRY LAB</td>
<td>WET LAB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OFTALMEDICA</td>
<td>HOYA</td>
</tr>
<tr>
<td>16:15 - 16:40</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:40 - 17:20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DRY LAB</td>
<td>WET LAB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OFTALMEDICA</td>
<td>HOYA</td>
</tr>
<tr>
<td>17:20 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DRY LAB</td>
<td>WET LAB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OFTALMEDICA</td>
<td>HOYA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day/Time</th>
<th>Room</th>
<th>AUDITORIUM</th>
<th>ROOM VERDE</th>
<th>ROOM ONICE</th>
<th>ROOM 9</th>
<th>ROOM 6</th>
<th>ROOM 4</th>
<th>SIMULATION ROOM</th>
<th>ROOM 101</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:30</td>
<td></td>
<td>FREE PAPERS</td>
<td>FREE PAPERS SURGICAL 3</td>
<td>FREE PAPERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td></td>
<td>ADVANCED SURGICAL COURSE:</td>
<td></td>
<td>MEDICAL 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>VITREORETINAL TECHNOLOGIES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:40</td>
<td></td>
<td>ADVANCED SURGICAL COURSE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>MACULAR SURGERY by GIVRE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:40 - 12:15</td>
<td></td>
<td>ADVANCED SURGICAL COURSE:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>MACULAR SURGERY by GIVRE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 - 13:00</td>
<td></td>
<td>EXTREME SURGERY COURSE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
13:00 - 15:00 FREE PAPERS - SURGICAL 1

ROOM VERDE
CHAIRS: Garcia-Arumi J., Hassan T., Moisseiev J., Steel D.
see page 40 for the detailed session

13:00 - 15:00 FREE PAPERS - MEDICAL 1

ROOM ONICE
CHAIRS: Bressler S., Brucker A., Loewenstein A., Viola F.
see page 42 for the detailed session

13:00 - 14:00 ADVANCED IMAGING by YORIS

AUDITORIUM
CHAIRS: Loewenstein A., Lumbroso B., Singh R.

13:00 Variations of choroidal thickness in neovascularization. Lumbroso B.
13:05 Imaging of retinal structures: seeing it up close with Adaptive Optics. Kim J.E.
13:10 The role of electrophysiology in the assessment of retinal function. Huang S.
13:15 Multimodal imaging in wet AMD: fibrocellular vs fibrovascular phenotypes. Querques G.
13:20 Discussion
13:25 Metabolic studies in AMD. Borrelli E.
13:30 Clinicopathologic correlation of geographic atrophy secondary to age-related macular degeneration. Dolz-Marco R.
13:35 Multimodal imaging in sickle cell retinopathy and incontinentia pigmenti. Liu A.
13:40 OCT-A and multimodal integrated evaluation in macular holes: new biomarkers of surgical outcome? Bacherini D.
13:45 Iris vessel changes assessed with OCT-A in episcleral surgery for retinal detachment. Mastropasqua R.
13:50 iOCT in gene therapy. Neubauer J.
13:55 Discussion
14:00 - 15:00 FOCUS ON OCT-A by SIR

CHAIRS: Mariotti C., Midena E.

14:00 Early AMD: novel functional biomarkers and their correlation with systemic risk factors. Minnella A.
14:05 Quantitative optical coherence tomography angiography biomarkers for neovascular age-related macular degeneration in remission. Lupidi M.
14:10 Choriocapillaris flow voids and outer retinal tubulations in geographic atrophy. Zweifel S.
14:15 Discussion
14:20 Update on OCT angiography in retinal vascular diseases. Schwartz S.G.
14:25 OCT-A in diabetic retinopathy. Battaglia Parodi M.
14:30 Distinguish diabetic macular edema from capillary non perfusion using two different OCTA devices. Parravano C.
14:35 Discussion
14:40 Multimodal imaging in hydroxycyloquoine toxicity. Pilotto E.
14:45 Multimodal imaging of tamoxifen retinopathy focusing on OCT angiographic findings. Yoon Y.H.
14:50 OCT-A in Uveitis. Androudi S.
14:55 Discussion

15:00 - 16:00 ESASO: Submacular treatments break through our real life clinic

AUDITORIUM

CHAIRS: Battaglia- Parodi M., Corcóstegui B., Falcomatà B., Guarnaccia G.

15:00 State of the art of inherited retinal dystrophies treatment. Richard G.
15:08 Indications and evaluation of patients for gene or stem cell therapy. Brucker A.
15:16 Surgical procedure for submacular delivery gene or stem cells therapy. Pertile G.
15:24 Update on retinal prosthesis: indications, surgical procedure and results. Patelli F.
15:32 Digitally enhanced video assisted surgery for submacular procedure. Devin F.
15:40 Use of ROCK inhibitors to prevent photoreceptor-bipolar synaptic disjunction after retinal detachment. Zarbin M.
15:48 Discussion
15:00 - 16:00 INTRAOCULAR TOXICITY COURSE

ROOM ONICE
CHAIRS: Pastor Jimeno J.C., Romano M.
15:00  A worrisome problem: the toxicity of perfluorocarbons liquids. Coco Martin R.
15:10  What do we know about the retinal toxicity of vital dyes? Januschowsky K.
15:20  How to recognize a case of acute intraocular toxicity. Pastor Jimeno J.C.
15:30  What do we need to look at in the choice of intraocular compounds? Romano M.
15:40  Can also irrigating solutions and expandable gases be sources of intra-surgical toxicity? Spitzer M.
15:50  Discussion

15:00 - 18:30 LIVE SURGERY

ROOM VERDE
CHAIRS FROM ROOM VERDE
D’Amico D.J., Dhawahir-Scala F., Rezaei K., Rossi T., Steel D.

CHAIRS FROM ORs
Kuwait City: Al Sabti K., EL Rayes E.
Memphis: Brugger J.
Mexico City: Fromow J.

SURGEONS
Kuwait City: Al Sabti K., Chow D., EL Rayes E., Maia A.
Memphis: Charles S.
Mexico City: Morales Canton V., Berrocal M.

16:00 - 16:30 COFFEE BREAK

16:30 - 17:30 MYOPIA

AUDITORIUM
CHAIRS: Figueroa M., Parolini B., Williamson T.
16:30  Natural history of serous retinal detachment in dome-shaped macula. Viola F.
16:35  OCT-A in myopic CNVs. Pece A.
16:40  Pathology of the VMI in myopic foveoschisis. Schumann R.G.
16:45  Discussion
16:50  Pearls an tricks dealing with myopic foveoschisis. Mateo C.
16:55 Myopic traction maculopathy and lamellar holes. *Figueroa M.*
17:00 Macular buckle. *van Meurs J.*
17:05 Discussion
17:10 Outcome of ILM inverted flaps and ILM peeling to the edge of the posterior staphyloma in myopic macular hole retinal detachment. *Mortada H.*
17:15 Myopic rhegmatogenous retinal detachment and macular schisis. *Williamson T.*
17:20 Autologous retina graft for high myopic macular holes. *Terasaki H.*
17:25 Discussion

**17:30 - 19:00 DIABETIC MACULAR EDEMA**

**AUDITORIUM**

**CHAIRS:** Bressler S., Brucker A., Lanzetta P., Zweifel S.

17:30 Do baseline systemic factors affect treatment outcomes in DME and diabetic retinopathy? *Singh R.*
17:35 Factors that affect vision or anatomic outcomes when treating DME - what we have learned in the DRCR.net. *Bressler S.*
17:40 The Role of Inflammation in diabetic macular edema. *Kupperman B.*
17:45 Discussion
17:50 One-Year results of using a treat-and-extend regimen without a loading phase with anti-VEGF agents in patients with treatment-naive diabetic macular edema. *Wolf S.*
17:55 Diabetic macular edema surgery: failure is the only option. *D’Amico D.J.*
18:00 Faricimab (RG7716) for DME: update on phase 2 BOULEVARD study results. *Regillo C.D.*
18:05 Discussion
18:10 A Phase I/II safety and efficacy study of Anti-PLGF THR-317 in diabetic macular edema. *Loewenstein A.*
18:15 Subthreshold micropulse laser in diabetic macular edema: how it really works. *Midena E.*
18:20 New drugs in pipeline for DME. *Boscia F.*
18:25 Discussion
18:30 Panel cases discussant. *Kupperman B., Singh R.*

**18:30 - 19:00 TRAUMA COURSE**

**ROOM VERDE**

**CHAIR:** Claes C.

**SPEAKERS:** Bali E., Hassan T., Kulikov A., Malachkova N., Mortada H., Mura M., Quiroz-Mercado H., Rezaei K., Gini G.
08:00 - 12:00 LIVE SURGERY

AUDITORIUM

CHAIRS FROM AUDITORIUM
Azzolini C., Binder S., De Molfetta V., Hassan T., Romano M.

CHAIRS FROM ORs
Florence: D’Amico D.J., Dhawahir-Scala F., Rezaei K., Steel D.
Kuwait City: Al Sabti K., Chow D.

SURGEONS
Florence: Coppola M., Boscia F., Caporossi T. Mateo C., Mura M., Priglinger S., Pertile G., Tadayoni R., Parolini B., Mariotti C.
Tel Aviv: Barak A.
Kuwait City: Kadonosono K., EL Rayes E., Oshima Y.
Sulzbach: Szurman P.

08:00 - 09:00 VASCULAR RETINAL DISEASES

ROOM VERDE

CHAIRS: Arevalo F., Friberg T., Lowenstein A., Parravano M.

08:00 Retinal vein occlusions: update on treatment options. Loewenstein A.
08:05 Neuroprotection for retinal diseases. Kupperman B.
08:10 Reversal of retinal ischemia after anti-VEGF therapy. Friberg T.
08:15 Discussion
08:20 Steroids in retinal vein occlusions. De Smet M.
08:25 Detection of retinal arterial microemboli after transcatheter aortic valve Implantation using SS-OCT-A. Zweifel S.
08:30 Radial Peripapillary Capillary (RPC) plexus vascular study in patients affected by Arteritic Ischemic Optic Neuritis (AION): new OCT-A diagnostic signs. Pierro L.
08:35 Discussion
08:40 Sickle cells maculopathy: new findings. Viola F.
08:45 Imaging and treatment of MacTel type 1. Nicolò M.
08:50  New Findings in MacTel2. *Spaide R.F.*

08:55  *Discussion*

---

**08:15 - 09:15 INHERITED RETINAL DISEASES**

**ROOM ONICE**

*CHAIRS: Da Cruz L., MacLaren R., Simonelli F., Sodi A.*

- **08:15**  Retinal dystrophies diagnosis. *Murro V.*
- **08:20**  Cone degeneration in retinitis pigmentosa: mechanisms and therapeutic strategies. *Falsini B.*
- **08:25**  Precision genome surgery for imprecise medicine. *Tsang S.*
- **08:30**  *Discussion*
- **08:40**  RPE65-gene therapy: our experience *Simonelli F.*
- **08:45**  Gene therapy for choroideremia. *MacLaren R.*
- **08:50**  Inhibition of retinal detachment-induced photoreceptor-bipolar cell synaptic disjunction with rho kinase inhibitors: potential impact on subretinal surgery for gene, cell-based, and retinal prosthesis therapy. *Zarbin M.*
- **08:55**  Surgical issues in retinal dystrophies. *Barca F.*
- **09:00**  *Discussion*

---

**09:00 - 10:00 VISION ACADEMY**

**ROOM VERDE**

*CHAIRS: Bandello F., Yoon Y.H.*

- **09:00**  What Vision Academy is. *Loewenstein A.*
- **09:05**  Management of submacular hemorrhage: surgery. *Figueroa M.*
- **09:10**  Management of submacular hemorrhage: anti-VEGF. *Gale R.*
- **09:15**  Management of submacular hemorrhage: viewpoint from the VA. *Behar Cohen F.*
- **09:20**  Treatment futility. Anti-VEGF treatment should be stopped when benefits are no longer expected. YES. *Viola F.*
- **09:25**  Treatment futility. Anti-VEGF treatment should be stopped when benefits are no longer expected. NO. *Koh A.*
- **09:30**  Treatment futility. Anti-VEGF treatment should be stopped when benefits are no longer expected. Viewpoint from the VA. *Wong D.*
- **09:35**  Optimal treatment regimen with anti-VEGF. Proactive. *Wolf S.*
09:40  Optimal treatment regimen with anti-VEGF. Reactive. **Bandello F.**
09:45  Optimal treatment regimen with anti-VEGF. Viewpoint from the VA. **Lanzetta P.**
09:50  Discussion

**09:15 - 10:00 LOW VISION**

**ROOM ONICE**

**CHAIRS:** Huang S., Lam L., Richard G.

09:15  Quality of life measurement in low vision patients. **Virgili G.**
09:20  Reading with a central deep scotoma. **Giacomelli G.**
09:25  Reading Aids for Central Low vision. **Volpe R.**
09:30  Discussion
09:35  Contrast sensitivity, light and low vision. **Farini A.**
09:40  Latest advances in technology in vision rehabilitation. **Lam L.**
09:45  Limitations of artificial vision - Retinachip. **Richard G.**
09:50  Discussion

**10:00 - 11:00 COFFEE BREAK**

**10:00 - 11:00 DIABETIC RETINOPATHY: EVIDENCES OF TOPICAL TREATMENT WITH NEUROPROTECTIVE AGENTS IN EYE DROPS**

**ROOM VERDE**

**CHAIRS:** García-Arumí J., Loewenstein A., Sesti G.

10:00  The pathogenesis of diabetic retinopathy. **Sesti G.**
10:15  Neuroprotection: a link between glaucoma and CNS degenerative disease. **Manni G.**
10:30  Neuroprotective effects of topical citicoline in models of retinal neurodegeneration. **Bandello F.**
10:45  First results of RCT in diabetic retinopathy: the first topical treatment to slow down retinal damage. **Parravano M.**
### 10:00 - 11:00 AFLIBERCEPT IN MACULAR DISEASES: SHAPE THE DIFFERENCE
**ROOM ONICE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00</td>
<td>Recent advance in DME treatment.</td>
<td>Midena E.</td>
</tr>
<tr>
<td>10.15</td>
<td>Proactive dosing.</td>
<td>Bandello F.</td>
</tr>
<tr>
<td>10.30</td>
<td>Aflibercept durability in retina pathologies.</td>
<td>Fornasari D.</td>
</tr>
<tr>
<td>10.45</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### 10:00 - 11:00 MACULAR EDEMA: THE ROLE OF INFLAMMATION
**ROOM 9**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00</td>
<td>Applications of OCT angiography in retinal edema.</td>
<td>Introini U.</td>
</tr>
<tr>
<td>10.15</td>
<td>Macular edema: a final common pathway of different retinal diseases.</td>
<td>Bacherini D.</td>
</tr>
<tr>
<td>10.30</td>
<td>Epidemiology and classification of uveitis and clinical approach to a patient with uveitis.</td>
<td>Miserocchi E.</td>
</tr>
<tr>
<td>10.45</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### 10:00 - 11:00 WHAT’S NEW IN RETINAL IMAGING
**ROOM 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.10</td>
<td>OCT Angiography: pearls and pitfalls.</td>
<td>Lupidi M.</td>
</tr>
<tr>
<td>10.20</td>
<td>Swept source versus spectral domain OCT: which are the differences?</td>
<td>Staurenghi G.</td>
</tr>
<tr>
<td>10.30</td>
<td>Looking at photoreceptors with a new confocal OCT software.</td>
<td>Faraldi F.</td>
</tr>
<tr>
<td>10.40</td>
<td>Radial Peripapillary plexus in diabetes.</td>
<td>Midena E.</td>
</tr>
<tr>
<td>10.50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### 11:00 - 12:00 DIABETIC RETINOPATHY
**ROOM VERDE**

**CHAIRS:** Avitabile T., Bressler N., Bressler S., Virgili G.

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Long term evaluation of diabetic retinopathy using OCT-A.</td>
<td>Parravano M.</td>
</tr>
<tr>
<td>11:05</td>
<td>Two bangs for one buck: rates of diabetic retinopathy improvement and worsening while treating DME.</td>
<td>Bressler S.</td>
</tr>
<tr>
<td>11:10</td>
<td>Clinical highlights of DRCR Network treatment regimen for diabetic macular edema.</td>
<td>Bressler N.</td>
</tr>
</tbody>
</table>
FRIDAY 7 JUNE

11:15  Discussion
11:20  Outcomes of anti-VEGF treatment for diabetic macular edema from clinical practice. Zweifel S.
11:25  Fluocinolone acetonide: real-world data in DME. Lattanzio R.
11:30  Vitreous hemorrhage in PDR: vitrectomy vs observation with/without anti-VEGF injections. Moisseiev J.
11:35  Discussion
11:40  Vitrectomy for DME unresponsive to pharmacologic therapy: is surgery beneficial? Arevalo J.F.
11:45  Tractional retinal detachment progression after preoperative anti-VEGF treatment: incidence and risk factors. Avitabile T.
11:50  Pearls for management of complicated proliferative diabetic retinopathy. Mortada H.
11:55  Discussion

11:00 - 12:00 BASIC RESEARCH

ROOM ONICE

CHAIRS: Augustin A., Behar Cohen F., Eandi C., Siqueira R.

11:00  Macular glial cells: do we know everything? Behar Cohen F.
11:05  In vivo (animal and human) application of histopathology and molecular biology to nAMD, diabetic macular edema, retinal detachment and vitreoretinal interface disorders. Tosi G.M.
11:10  The role of mitochondrial genetics in age related macular degeneration. Kupperman B.
11:15  Discussion
11:20  On phagocytes and macular degeneration. Eandi C.
11:25  Pharmacological strategies for improving RPE transplant survival in AMD eyes. Zarbin M.
11:30  Inflammatory retinal biomarkers in clinical models. Pilotto E.
11:35  Discussion
11:40  Role of inflammation in retinitis pigmentosa: inflammation markers in the aqueous humour. Bacherini D.
11:45  The future of cell derived therapies for retinal degenerative disease. Binder S.
11:50  Role of Muller cells in horizontal gliosis: how to close the large hole. Romano M.
11:55  Discussion
12:00 - 13:00 3D RETINAWS

AUDITORIUM

PANELISTS: Bali E., Devin F., Eckardt C., Figueroa M., Garcia-Arum J., Mura M., Murray T.G., Rezaei K.

12:00 - 13:00 MACULOPATHIES: PACHYCHOROID

ROOM VERDE

CHAIRS: Behar Cohen F., Brucker A., Spaide R., Staurenghi G.

12:00 Update on pachychoroid spectrum disease. Spaide R.F.
12:05 Going deeper: advances in choroidal imaging. Staurenghi
12:10 Pachychoroid neovasculopathy: aspect on OCT angiography. Savastano M.
12:15 Early response to the treatment of CNV complicating central serous retinopathy: an OCT-A study. Querques G.
12:20 Discussion
12:25 Risk factors for central serous retinopathy. Schwartz S.D.
12:30 Multimodal imaging in the diagnosis and treatment of the Polypoidal Choroidal Vasculopathy. Ciardella A.
12:35 The role of mineralocorticoid receptor antagonists in pachychoroid and choroidal neovascularization. Behar Cohen F.
12:40 Photodynamic therapy for central serous chorioretinopathy. Eandi C.
12:45 Discussion

12:00 - 13:00 PEDIATRIC RETINA ADVANCED COURSE

ROOM ONICE

CHAIRS: Capone A.J., Claes C., Saravia M., Trese M.

12:00 Microvascular analysis of familiar exudative vitreoretinopathy using OCT-A. Capone A.J.
12:05 FEVR surgical treatment. Barca F.
12:10 Tips for the diagnostic and treatment of Stickler disease. Corcostegui B.
12:12 Discussion
12:20 Coats exudative retinal detachment treated with drainage of subretinal fluid, anti-VEGF and wide-field guided laser. Mastropasqua R.
12:25 Pediatric macular holes. Ferrone P.
12:30 Long term outcome of combined vitrectomy and extensive ILM peeling in complicated pediatric rhegmatogenous retinal detachments. Mortada H.

11:35 Discussion

12:40 Ultra-wide field angiography in the management of Eales disease. Kumar V. (Floretina L. Barca Award 2017)

12:45 Telemedicine for ROP management. Trese M.

12:50 Surgery in persistent fetal vasculature. Saravia M.

12:55 Discussion

13:00 - 14:10 LUNCH

13:00 - 14:00 ADVANCED SOLUTION TO ENHANCE THE VITREORETINAL PROCEDURE

AUDITORIUM

MODERATOR: Boscia F.

13:00 Introduction. Boscia F.

13:02 Upgrade vitreoretinal surgeries with the advanced capabilities of the surgical equipment. Claes C.

13:14 Images modes customization to see more and do more: a milestone in 3D digital visualization. Figueroa M.

13:26 DATAFUSION™ - Full integration of 3D Visualization in your surgical system. Mura M.

13:38 Leverage a complete vitreoretinal portfolio at every step of the surgery. Boscia F.

13:50 Discussion

13:00 - 14:00 IT'S RIVAL TIME!

ROOM VERDE

13:00 Introduction. Bandello F.

13:05 RIVAL trial: rationale and scientific relevance. Battaglia Parodi M.

13:20 How evidences on efficacy change after RIVAL? Vujosevic S.

13:35 Individualized treatment for an optimal outcome. Nicolò M.

13:50 Discussion
13:00 - 14:00 NEW FRONTIERS IN RETINAL IMAGING: OCT ANGIOGRAPHY AND MULTIMODAL INTEGRATED EVALUATION

ROOM ONICE
MODERATORS: Schwartz S.D, Staurenghi G.
13:00 The importance of multimodal imaging: the new SLO+OCT retinal platform. Staurenghi G.
13:10 How OCT angiography is changing retina practice: quantitative assessment of the retinal microvasculature. Schwartz, S.
13:30 From diagnosis to visual rehabilitation: new applications of MP-3 Microperimeter. De Rossi F.
13:40 Discussion

13:00 - 14:00 MICRONUTRIENTS AND BENEFITS OF SUPPLEMENTATION FOR REDUCING THE RISK OF RETINOPATHIES PROGRESSION

ROOM 9
13:00 Lecture: Nutritional supplement as therapeutic approach to Dry AMD. Arrigo A.
13:30 Lecture: Role of micronutrients in the management of exudative maculopathy. Scuderi G.

13:00 - 14:00 SHARING EXPERIENCES IN THE APPLICATION OF INNOVATIVE VITREORETINAL LIQUIDS

ROOM 4
CHAIR: Romano M.
13:00 Introduction - Value of purity. Romano M.
13:07 Effects of a silicone oil solving agent on corneal endothelial cells. Spitzer M.
13:14 Long-term experiences with heavier-than-water dyes in retinal surgery. Gerding H.
13:21 Silicone oil with extended viscosity in routine surgery. Bertelli E.
13:28 High viscosity silicone oil with extended viscosity in small gauge surgery. Chelini P.
13:35 Experiences with heavy silicone oil in retinal surgery. Parolini B.
13:42 Discussion
14:00 - 15:00 RETINAL DETACHMENT

AUDITORIUM

CHAIRS: Garcia Arumi J., Heimann H., Johnson M.

14:00 29 g directional spotlight - a new chandelier system. Eckardt C.
14:05 ILM peeling for retinal detachment: should I do it? Shah G.K.
14:10 Retinal complications of long term silicone oil tamponades. Friberg T.
14:15 Discussion
14:20 Vitrectomy vs scleral buckling for primary retinal detachment: where are we today? D’Amico D.J.
14:25 Simplifying buckling surgery technique. Corcostegui B.
14:30 Staining in PVR. Garcia-Arumi J.
14:35 Discussion
14:40 Only air tamponade in retinal detachment is possible? Bali E.
14:45 Repair of retinal detachment without vitrectomy adjuncts. Johnson M.
14:50 Visual acuity recovery after retinal detachment: what can adaptive optics teach us? Wolfensberger T.
14:55 Discussion

15:00 - 15:55 WET AMD by ASRS

AUDITORIUM

CHAIRS: Ferrone P., Kim J.E., Shah G.

15:00 Treatment regimens for neovascular AMD - where does the evidence point us? Bressler S.
15:05 Recent Updates from the AREDS2 Study. Kim J.E.
15:10 Outcomes of anti-VEGF treatment for CNV in fellow eyes of previously treated patients with Wet AMD. Hassan T.
15:15 Discussion
15:20 Improving outcomes for patients with intermediate AMD: the role of genetic testing. Awh C.
15:25 The Port Delivery System with ranibizumab for neovascular AMD: phase 2 LADDER results and phase 3 ARCHWAY study design. Regillo C.D.
15:30 Anti-VEGF gene therapy for AMD. Schwartz S.D.
15:35 Challenges in the application of clinical trial results to clinical practice. Zarbin M.
15:40 Discussion
15:55 - 16:15 FUTURE PERSPECTIVES IN OPHTHALMOLOGY

AUDITORIUM

BAUSCH+LOMB: Calvin W. Roberts (Senior Vice President, Chief Medical Officer)
BAYER: Rafiq Hasan (Global Head of Ophthalmology)
DORC: Thierry Leclerq (Chief Executive Officer)
CARL ZEISS: Thorsten Tritschler (Director Product Management Ophthalmic Surgery Systems, Medical Technology Business Group)

16:15 - 16:45 COFFEE BREAK

16:45 - 17:35 PEDIATRIC RETINA

AUDITORIUM

CHAIRS: Barca F., Campos E., Capone A., Trese M.

16:45  Vitreoretinal interface in prematures. Claes C.
16:50  Best approaches for pediatric retinal detachments. Ferrone P.
16:55  Lensectomy when and how. Barca F.
17:00  Discussion
17:05  Management of stage 4 ROP in the anti-VEGF era. Capone A.J.
17:10  ROP stage 5: do we still have to perform surgery? Mura M.
17:15  A developing regenerative therapeutic for retinal vascular disease. Trese M.
17:20  Advanced treatment for complex retinoblastoma. Murray T.G.
17:30  Discussion

17:35 - 18:20 INNOVATIONS

AUDITORIUM

CHAIRS: Da Cruz L., van Meurs J.

17:35  Gene therapy and CRISPR-mediated gene editing. Huang S.
17:40  Eye606 non viral gene therapy for non infectious posterior uveitis; result from phase Ib/ Ila trial. Baggage R.
17:45  Stem cell therapy for maculopathies. Schwartz S.D.
17:50  Discussion
17:55  LCA Therapy: from fiction to fact. B. Leroy
18:00  New strategies of treatment of the Stargardt disease. Simonelli F.
18:05  AR/VR (augmented/virtual reality) devices in patients with advanced AMD or other retinal diseases. Lam L.
18:10  Discussion

18:20 - 19:00 IS IT TIME FOR THE AGE OF ROBOTS?

AUDITORIUM

CHAIRS: De Smet M., Schwartz S.D., Williams G.

18:20  Robotic surgery as a delivery tool for novel retinal therapies. Da Cruz L.
18:25  Robotic surgery - Promises, challenges and reality. De Smet M.
18:30  Performance of robotics in macular pucker surgery - preliminary results of a randomized study. Faridpooya K.
18:35  Discussion
18:40  Comparison of robotic and manual surgery for internal limiting membrane peeling. Maberley D.
18:45  A novel micro-surgical robot: preliminary experiences. Savastano A.
18:50  Robotics: a means to automate surgery. Schwartz S.D.
18:55  Discussion
08:00 - 12:00 LIVE SURGERY

AUDITORIUM
CHAIRS FROM AUDITORIUM
Arpa P., Berrocal M., Morales Canton V., Nikolakopoulos A., Romano M., Williamson T.

CHAIRS FROM ORs
Florence: D’Amico D.J., Dhawahir-Scala F., Rezaei K., Steel D.
Athens: Gotzaridis S., Parikakis S.

SURGEONS
Florence: Patelli F., Bali E., Garcia Arumi J., Caretti L., Eckardt C., Claes C., Lanzetta P., Tognetto D., Rizzo S.
Lugano: Pournaras J.A.

08:00 - 09:10 AMD: NEW DIAGNOSTIC AND TREATMENT STRATEGIES

ROOM VERDE
CHAIRS: Boscia F., Rosenfeld P.J., Singh R.

08:00 Natural history of subclinical, non-exudative macular neovascularization in AMD. Rosenfeld P.J.
08:05 Quantitative vascular density changes in choriocapillaris around CNV after anti-VEGF treatment: dark halo Rispoli M.
08:10 A Comparison among different automated segmentation algorithms to assess neovascular AMD using swept source optical coherence tomography angiography. Parravano M.
08:15 Discussion
08:20 Early findings of Type 3 neovascularization with swept-source angio-oct. Nicolò M.
08:25 Treat and extend anti-VEGF drugs regimen for neovascular AMD. Boscia F.
08:30 Can we achieve quarterly dosing in exudative AMD? Singh R.
08:35 Discussion
08:40 Bilateral therapeutic response to unilateral anti-VEGF injection in various diseases in neovascular AMD. Schwartz S.G.
08:45  Non-responders to anti-VEGF therapy - How often do we see them? What to do? Richard G.
08:50  A new form of meta-analysis for ranibizumab and aflibercept dosing. Spaide R.F.
08:55  Discussion

08:00 - 10:00 RETINAL DETACHMENT ADVANCED COURSE

ROOM ONICE

CHAIRS: Nadal J., Ogura Y., Regillo C., van Meurs J.
08:00  Progression of retinal detachment. van Meurs J.
08:05  Does the choroid play a role in retinal detachment progression? Wolfensberger T.
08:10  Muller cells genetic modulation and retinal detachment. Azzolini C.
08:15  Macular Optical Coherence tomography findings after vitreoretinal surgery for rhegmatogenous retinal detachment. Coppola M.
08:20  Discussion
08:25  The role of scleral buckling in primary and complex retinal detachment repair: evidence and personal experience. Regillo C.D.
08:30  Scleral buckling after LASIK surgery: practical considerations. Friberg T.
08:35  Using the principle of buckling for retinal detachments in modern ways. Binder S.
08:40  Discussion
08:45  Phaco-combined vitrectomy for primary retinal detachment: a consecutive series of 340 cases in an ambulatory surgical center. Oshima Y.
08:50  Primary retinal detachment: vitrectomy with air tamponade. Rapizzi E.
08:55  Retinal detachment in Morning Glory Syndrome. Ferrara V.
09:00  Discussion
09:05  Safe gas bubble use in RD. Williamson T.
09:10  Management of intrusion of buckle and recurrent RD. Soni M.
09:15  Why I use heavy silicone oil? Mateo C.
09:20  Discussion
09:25  How PVR surgery is changing. Nadal J.
09:30  PPV for Rhegmatogenous retinal detachment in uveitis. Androudi S.
09:35  Discussion
09:10 - 10:00 ENDOPHTHALMITIS

ROOM VERDE

CHAIRS: Faraldi F., Moisseiev J., Schwartz S.G., Zweifel S.

09:10 Are the EVS guidelines for management of post-operative endophthalmitis still relevant? Moisseiev J.
09:15 Endophthalmitis treatment: earlier antibiotics, later diagnosis with improved PCR. van Meurs J.
09:20 Medical and surgical management of fungal endophthalmitis. Chizzolini M.
09:25 Endogenous endophthalmitis. Agrawal R.
09:30 Discussion
09:35 A new potential strategy for a “resistance-free” preoperative prophylaxis. Franchini I.
09:40 Leader 7 Study: new evidence in medical treatment after ophthalmic surgery. Bandello F.
09:45 Needles and syringes as sources of silicone oil during intravitreal injection. Melo G.
09:50 Endophthalmitis after intravitreal anti-VEGF injections: infection rates, prophylaxis, and distinguishing infectious endophthalmitis from non-infectious inflammation. Schwartz S.G.
09:55 Discussion

10:00 - 11:00 COFFEE BREAK

10:00 - 11:00 FLUID CONTROL IN WET AMD

ROOM VERDE

10.00 Pharmacological properties of intravitreal aVEGF agents: focus on innovative molecules. Danesi R.
10.15 Disease activity assessment as driver of treatment: which parameters? Viola F.
10.30 How much can we dry the retina? Staurenghi G.
10.45 Innovation is on the horizon: new therapies in wAMD. Danesi R.

10:00 - 11:00 DME PATIENTS REAL LIFE EXPERIENCE WITH FLUCINOLONE ACETONIDE FROM BOTH SIDES OF THE ATLANTIC

ROOM ONICE

MODERATOR: Bandello F.
10:00 Three years data from Germany with fluocinolone acetonide. Augustin A.
10:15 Advantage of continuous microdosing: San Raffaele Hospital experience. Bandello F.
10:30 US real world data with fluocinolone acetonide. Kim J.
10:45 Discussion

10:00 - 11:00 ADAPTIVE OPTICS

ROOM 9
CHAIRS: Paques M., Sodi A.
10:00 Clinical applications of adaptive optics ophthalmoscopy in 2019: a constellation of niches. Paques M.
10:10 Standard clinical procedures for AOO using the rtx1 camera: photoreceptor and vessel imaging. Finocchio L.
10:20 Surgical diseases observed by AOO: epiretinal membranes, retinal detachment, macular holes. Paques M.
10:30 High resolution vascular imaging: static and dynamic. Castro Fariás D.
10:40 Microscopic diagnosis: the example of Fabry’s disease. Sodi A.
10:50 Adaptive optics ophthalmoscopy in arterial hypertension. Rizzoni D.

11:00 - 13:00 FREE PAPERS – SURGICAL 2

ROOM ONICE
CHAIRS: Lesnioni G., Nikolakopulos A., Panozzo G., Schwart S.D.
see page 45 for the detailed session

11:00 - 12:00 TUMORS

ROOM VERDE
CHAIRS: Balestrazzi E., Damato B., Heimann H., Murray T., Wolfensberger T.
11:00 Multimodal imaging in intraocular tumors. Scupola A.
11:05 Does early treatment of choroidal melanoma have an influence on the rate of metastatic disease? Heimann H.
11:10 Choroidal tumour biopsy. Damato B.
11:15 Discussion
11:20 Surgery in ocular tumors (VHL, melanoma, vasoproliferative). Maia A.
11:20 Role of vitreoretinal surgery in maximizing treatment outcome following complications after proton therapy for uveal melanoma. Wolfensberger T.
11:30  Clinical outcome after Ru106 Brachytherapy or Gamma Knife radiosurgery in uveal melanoma. Mazzini C.
11:35  Discussion
11:40  Prevention and treatment of radiation maculopathy. Midena E.
11:45  Treatment of exudative retinal vascular malformations. Mura M.
11:50  Intraocular lymphoma: recognize and treat. Angi M.
11:55  Discussion

**12:00 - 13:00 HOW DO I DO IT: 3D VIDEO PANEL**

**AUDITORIUM**

MODERATOR: El Rayes E.

**12:00 - 13:00 UVEITIS**

**ROOM VERDE**

CHAIRS: Agrawal A., Androudi S., De Smet M., Vannozzi L.
12:00  Inflammation or atrophy, this is the question. Accorinti M.
12:05  A practical approach to retinal vasculitis. Cimino L.
12:10  Diagnostic pars plana vitrectomy. Vannozzi L.
12:15  Discussion
12:20  Placoid maculopathies. Introini U.
12:30  Tip and tricks on how to survive in the jungle of immune-therapy in uveitis. Neri P.
12:35  Discussion
12:40  Approach to tuberculous uveitis. Agrawal R.
12:45  Toxoplasmosis chorioretinitis: current treatments. De Smet M.
12:50  Surgery for infectious retinitis when medical therapy is not sufficient. Arevalo J.F.
12:55  A novel vitreous surgery to remove intraocular cysticercosis. Natarajan S.
13:00  Discussion

**13:00 - 14:00 LUNCH**
13:00 - 14:00 TREATING DME: RECOMMENDATIONS FROM THE EXPERTS

AUDITORIUM

MODERATORS: Bandello F., Loewenstein A.
13:00 Welcome and introduction. Bandello F., Loewenstein A
13:02 Unmet needs in treating DME in real life. Bandello F.
13:14 Seeking consensus in DME management: findings from Germany. Augustin A.
13:26 Real-world experience with dexamethasone implant. Maia M.
13:38 Treating DME patients undergoing cataract surgery: ‘tips and tricks’. Kupperman B.
13:50 Discussion

13:00 - 14:00 INNOVATION IN RETINAL DIAGNOSIS

ROOM VERDE

MODERATORS: Parravano M., Shah G.K., Staurenghi G.
13:00 Next generation ultra-widefield angiography. Staurenghi G.
13:15 Latest advancements in OCT Angiography and retina diagnostics part 1. Parravano M.
13:30 Latest advancements in OCT Angiography and retina diagnostics part 2. Shah G.K.
13:45 Discussion

13:00 - 14:00 TRANSFORMING RETINAL SURGERY THROUGH PIONEERING TECHNOLOGY

ROOM ONICE

MODERATOR: Avitabile T.
13:00 The Advantages of Dual Port Cutter technology. De Cillà S.
13:12 From cutting to liquefaction. Le Mer Y.
13:24 The learning curve of Hypersonic Vitrectomy. Bali E.
13:36 Hypersonic Vitrectomy - Experimental study. Stanga P.
13:48 Discussion
13:00 - 14:00 INNOVATION IN VITREORETINAL SURGERY:
A NEW MOLECULE OF BLUE

ROOM 9
CHAIRS: Pileri M.A., Romano M.
13:00 A close look at a new Blue dye: an innovative recently developed molecule. Spadaro A.
13:10 From preclinical development to clinical application. Romano M.
13:20 Are all Intraocular dyes toxic? Safety of lutein-based dyes. Coppola M.
13:30 ILM Peeling: when and why?
13:40 New Trends in chromovitrectomy. Romano M.
13:50 Discussion

13:00 - 14:00 UPDATE ON OCRIPLASMIN REAL WORLD EVIDENCE IN ITALY

ROOM 6
MODERATORS: Barca F., Cacciamani A., Cereda M.
13:00 Introduction: overview of recent study data on ocriplasmin. Barca F.
13:10 Experience from Careggi Hospital, Florence. Giuntoli M.
13:15 Short term vitreous modifications following ocriplasmin. Experience from Bietti Foundation, Rome. Cacciamani A.
13:30 Ocriplasmin for VMT: A look outside the macula. Experience from Sacco Hospital, Milan. Cereda M.
13:45 Question & Answer: Critical patient selection criteria identified by real world evidence on ocriplasmin

13:00 - 14:00 THE STANDARD OF CARE FOR RETINITIS PIGMENTOSA:
THE EPI-RETINAL PROSTHESIS SYSTEM

ROOM 4
MODERATOR: Cinelli L.
13:00 Long term results of the biggest Argus II patients center: benefits and complications. Cinelli L.
13:15 Use of Intraoperative OCT in ensuring optimal array-retina contact during Argus II implantation surgery. Yoon Y.H.
13:45 Discussion
14:00 - 15:00 PROLIFERATIVE DIABETIC RETINOPATHY

**AUDITORIUM**

**CHAIRS:** Arevalo J.F., Bressler N., Le Mer Y., Stanga P.
14:00 OCT-A and FA findings after anti-VEGF PDR treatment. Tadayoni R.
14:05 Clinical highlights of DRCR Network treatment regimen for proliferative diabetic retinopathy. Bressler N.
14:10 Can we predict which eyes with PDR do best with anti-VEGF vs PRP? Bressler S.
14:15 Anti-VEGF monotherapy for ischemic diabetic retinopathy: consequences of inadvertent treatment Interruptions. Johnson M.W.
14:20 Discussion
14:35 Pre-Operative Intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy. Arevalo J.F.
14:40 Machines, settings and instrumentation for the new PDR vitrectomy. Morales-Canton V.
14:45 Surgical management of PDR advances in techniques are improving surgical outcomes. Berrocal M.
14:50 Discussion

15:00 - 16:00 MACULAR HOLE

**AUDITORIUM**

**CHAIRS:** Awh C., Binder S., Boscia F., Devin F.
15:00 Intraoperative OCT for difficult macular surgery. Binder S.
15:05 Adaptive optics imaging of macular holes and epiretinal membranes: pre and post operatory evaluation of foveal healing Paques M.
15:10 When operating for macular hole, ERM and VMT: combined phacovitrectomy vs vitrectomy and sequential cataract operation. Moisseiev J.
15:15 Induced PVD with TPA and SF6 in patients with symptomatic VMT. Lafetà A.
15:20 From combined phacovitrectomy to femtophacovitrectomy in macular surgery. Faraldi F.
15:25 Discussion
15:30 Autologous Platelet-rich plasma for myopic macular holes. Is it useful for Macular Holes with retinal detachment? Figueroa M.
15:35 Inverted flap for large idiopathic macular hole surgery: is there any advantage for the post-surgical remodelling of the outer retinal layers? Bottoni F.
15:40   Retinal relocation for large recurrent macular holes. Claes C.
15:45   Autologous retinal transplant world experience. Mahmoud T.
15:50   Amniotic membrane in macular hole surgery. Caporossi T.
15:55   Discussion

16:00 - 16:15 FUTURE PERSPECTIVES IN OPHTHALMOLOGY

AUDITORIUM
ALCON: Michael Onuscheck (President, Global Business & Innovation)
ALLERGAN: Montu Sumra (Executive Director, Medical Affairs, Eyecare)
NOVARTIS: Nikolaos Tripodis (Worldwide Head Ophthalmology)

16:15 - 16:40 COFFEE BREAK

16:40 - 17:20 DRY AMD BY EURETINA

AUDITORIUM
CHAIRS: Rizzo S., Wolf S.
16:40   Dry AMD classification. Staurenghi G.
16:45   Impact of drusen and drusenoid retinal pigment epithelium elevation size and structure on RPE integrity. Schmidt-Erfurth U.
16:50   Fluorescence lifetime imaging ophthalmoscopy in Dry AMD. Wolf S.
16:55   Adaptive optics in Dry AMD. Paques M.
17:00   Recent advances in the management of Dry AMD. Querques G.
17:05   The use of stem cells for retinal therapies. Da Cruz L.
17:10   Amniotic membrane in Dry AMD. Rizzo S.
17:15   Discussion
## 17:20 - 18:00 ARTIFICIAL INTELLIGENCE

**AUDITORIUM**

**CHAIRS:** Mahmoud T., Schmidt-Erfurth U., Tadayoni R., Williams G.A.

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:20</td>
<td>Artificial Intelligence in retina: a constructive revolution.</td>
<td>Schmidt-Erfurth U.</td>
</tr>
<tr>
<td>17:25</td>
<td>How Artificial Intelligence improves insight into OCT-A imaging.</td>
<td>Spaide R.F.</td>
</tr>
<tr>
<td>17:30</td>
<td>Screening for AMD at home using Artificial Intelligence.</td>
<td>Loewenstein A.</td>
</tr>
<tr>
<td>17:35</td>
<td>Artificial Intelligence in diabetic retinopathy.</td>
<td>Tadayoni R.</td>
</tr>
<tr>
<td>17:40</td>
<td>Big data in the real world and Artificial Intelligence.</td>
<td>Williams G.A.</td>
</tr>
<tr>
<td>17:45</td>
<td>Artificial Intelligence in age-related macular degeneration - where are we? Where are we going?</td>
<td>Bressler N.</td>
</tr>
<tr>
<td>17:50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

## 18:00 - 19:00 IMAGING

**AUDITORIUM**

**CHAIRS:** Bottini F., Rosenfeld P.J., Spaide R., Staurenghi G.

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00</td>
<td>Comparison of ultrawide field technologies.</td>
<td>Singh R.</td>
</tr>
<tr>
<td>18:05</td>
<td>Wide-field imaging in pediatric retinal diseases.</td>
<td>Capone A.J.</td>
</tr>
<tr>
<td>18:10</td>
<td>Wide-field OCT vs ultrawide field fluorescein angiography for the assessment of retinal vasculopathies.</td>
<td>Tadayoni R.</td>
</tr>
<tr>
<td>18:15</td>
<td>OCT angiography vs dye-based angiography in neovascular choroidal diseases.</td>
<td>Staurenghi G.</td>
</tr>
<tr>
<td>18:20</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:25</td>
<td>What is a treatment-naive quiescent type 1 macular neovascularization really?</td>
<td>Querques G.</td>
</tr>
<tr>
<td>18:30</td>
<td>New proposal for the pathophysiology of type 3 neovascularization as based on multimodal imaging findings.</td>
<td>Spaide R.F.</td>
</tr>
<tr>
<td>18:35</td>
<td>Imaging of the choroidal vasculature using SS-OCT.</td>
<td>Rosenfeld P.J.</td>
</tr>
<tr>
<td>18:40</td>
<td>SS-OCT angiographic imaging of the choriocapillaris in macular diseases.</td>
<td>Rosenfeld P.J.</td>
</tr>
<tr>
<td>18:45</td>
<td>OCT angiography and macular function.</td>
<td>Midena E.</td>
</tr>
<tr>
<td>18:50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
08:00 - 09:30 FREE PAPERS - SURGICAL 3

ROOM VERDE
CHAIRS: Binder S., Kadonosono K., Micelli Ferrari T., Tognetto D.
see page 47 for the detailed session

08:00 - 10:00 FREE PAPERS - MEDICAL 2

ROOM ONICE
CHAIRS: Lanzetta P., MacLaren R., Zweifel S.
see page 49 for the detailed session

09:30 - 10:40 ADVANCED SURGICAL COURSE VITREORETINAL TECHNOLOGIES

AUDITORIUM
CHAIRS: Beltrame G., EL Rayes E., Heimann H., Mortada H., Rossi T.
09:30 Nitinol basket for sutureless lens fragmentation. Mura M.
09:35 Troubles with IOL’s. Mateo C.
09:40 Closure of sclerotomies - My technique. Eckardt C.
09:45 Chandeliers a gadget or a must. Bali E.
09:50 Digital enhanced images on 3D vitrectomy. Kadonosono K.
09:55 Endoscopy and Ngenuity. Maia A.
10:00 Discussion
10:05 27-Gauge vitrectomy: where are we now? Oshima Y.
10:10 Stiffness and displacement analysis of 23-, 25-, and 27 gauge vitreous forceps. Tognetto D.
10:15 Combined femtophaco-vitrectomy - tips and tricks. Richard G.
10:20 The hypersonic setting: what we need to know on stroke and vacuum to set the best fluid balance. Romano M.
10:25 Digitally enhanced endoscopy-assisted VR surgery for severe anterior PVR. Rezende F.
10:30 3D Surgery: providing the best from digital imaging. Vinciguerra P.
10:35 Discussion
10:40 - 12:15 ADVANCED SURGICAL COURSE MACULAR SURGERY BY GIVRE

AUDITORIUM

CHAIRS: Al Sabti K., Lesnoni G., Tognetto D., Zenoni S.

10:40 Lamellar macular hole: morphological and functional characterization. Azzolini C.
10:45 Vitrectomy for the treatment of tractional and degenerative lamellar macular holes. Results of a multicenter study. Figueroa M.
10:50 Macular hole closure after human amniotic membrane plug transplantation: when air endotamponade is not enough. Fiore T.
10:55 Temporal inverted ILM flap could be a standard treatment methods for large macular holes. Avci R.
11:00 Vitrectomy for myopic macular schisis. Giansanti F.
11:05 Unusual course of operated macular holes. Panozzo G.
11:10 Discussion
11:15 Pathogenesis and treatment of cavitary optic disc maculopathy. Johnson M.
11:20 Autologous retinal transplantation for eyes with secondary large macular hole. Kadonosono K.
11:25 Subretinal hemorrhage displacement with subretinal air. Mahmoud T.
11:30 Comparison between 25-Gauge and 27-Gauge 3D visualization system-assisted vitrectomy in macular surgery. Mariotti C.
11:35 Macular buckles when and how. Mura M.
11:40 Discussion
11:45 Guidelines to the management of myopic traction maculopathy based on the new MTM Italian staging system. Parolini B.
11:50 Dexamethasone implant for the treatment of advanced stage epiretinal membrane. Peiretti E.
11:55 Towards a new classification for large macular holes. Rezende F.
12:00 ILM multiple folding under PFCL for large and chronic macular holes. Rossi T.
12:05 Vitrectomy surgical treatment without tamponade for optic pit maculopathy. Rapizzi E.
12:10 Discussion
**12:15 - 13:00 EXTREME SURGERY COURSE**

**AUDITORIUM**

**CHAIRS:** Avci R., Coppola M., Damato B., Garcia Arumi J., Mahmoud T.

- **12:15** Surgical treatment for neovascular glaucoma. *Maia A.*
- **12:20** Surgical outcomes of primary Vit/Buckle with gas tamponade for PVR due to peripheral retinal vascular diseases. *Oshima Y.*
- **12:25** Transretinal tumour biopsy of small choroidal tumours with a thickness of ≤2 mm. *Heimann H.*
- **12:30** *Discussion*
- **12:35** Local resection of choroidal melanoma. *Damato B.*
- **12:40** Vitrectomy for advanced intraocular malignancies. *Murray T.G.*
- **12:45** Surgery in uveitis (general tips and concerns, pre- and post-operative management). *Androudi S.*
- **12:50** Surgical treatment of retinal vasoproliferative tumors complicated with advanced exudative retinal detachment and proliferative vitreoretinopathy. *Avci R.*
- **12:55** Vitreoretinal surgery for an eye injury. *Kulikov A.*
- **13:00** *Discussion*
COURSES

16:30 - 18:30 NURSE COURSE

ROOM ONICE

SCIENTIFIC COORDINATORS: Turrisi L, Zucchini D.

16.30 Introduction
16:40 New technologies in ophtalmic surgery: nurses skills. Pratesi L, Morroni S.
16.50 The new integrated vitreoretinal operating theatre. Salonen S.
17.00 What about eye trauma? Jansen K.
17.10 Transforming retinal surgery through pioneering technology. Bollini S.
17.20 Driving OR flow optimization and single use through customization of the procedural pack. Vatovec C.
17.30 Visualization systems in retina surgery. Oller Garcia M.
17.40 The 3D System in the vitreoretinal surgery. Tescaro S.
17.50 EVA Upgrade - Dedicated to OR efficiency. Canali F.
18.00 A phaco for Africa: a humanitarian project. Spiridigiozzi M.
18.10 Discussion

14:00 - 15:00 AIORAO COURSE: INSTRUMENTAL SEMEIOITICS FOR RETINAL DISEASE

ROOM ONICE

MODERATORS: Campos E., Drago D., Huang S., Lam L.
14:00 Retcam imaging for Retinopathy of prematurity screening. Zavolini M.
14:05 The orthoptic in the ocular electrophysiology clinic. Placidi G.
14:10 Adaptive optics in ophtalmology; early diagnosis in retinal diseases. Cipollini F.
14:15 Choroidal and retinal imaging with OCT. Biagini I.
14:20 Microperimetry in macular diseases. Convento E.
14:25 Discussion
14:35 Electrophysiology and modern indications. Huang S.
14:40 Wide-field imaging in pediatric retinal disease. Capone A.J.
14:45 Innovations in low vision rehabilitation. Lam L.
14:50 Discussion
WET and DRY LABS

Wet and Dry Labs will be available all day for the duration of the conference as per specified times.

**DRY LAB OFTALMEDICA**
Surgical Simulator by VRmagic

- Thursday 6 June 13:00 - 19:00
- Friday 7 June 08:00 - 19:00
- Saturday 8 June 08:00 - 19:00
- Sunday 9 June 08:00 - 13:00

**WET LAB HOYA**

- Friday 7 June 10:00 - 17:00
- Saturday 8 June 08:30 - 17:00
- Sunday 9 June 08:30 - 12:00

**WET LAB DORC**

- Friday 7 June 08:00 - 19:00
THURSDAY 6 JUNE

13:00 - 15:00 FREE PAPERS - SURGICAL 1

ROOM VERDE

CHAIRS: Garcia-Arumi J., Hassan T., Moisseiev J., Steel D.

OS1 - 01  THE ROLE OF THE ANAESTHESIOLOGIST IN VITREO-RETINAL SURGERY: A PATIENT’S SATISFACTION PERSPECTIVE.
C. Adembri, G. Cecchi, I. Cappellini, S. Degl’innocenti, G. Pellegrini

OS1 - 02  CLINICAL CHARACTERISTICS AND SURGICAL OUTCOMES IN PEDIATRIC RHEGMATOGENOUS RETINAL DETACHMENT.
I. Akkoyun, C. Öztürk, G. Yilmaz, S. Cezairlioglu

OS1 - 03  NOVEL TECHNIQUE OF STAINING INTERNAL LIMITING MEMBRANE IN RETINAL DETACHMENT.
M. Bansal

OS1 - 04  PLAIN SCLERAL BUCKLING FOR RHEGMATOGENOUS RETINAL DETACHMENT.
M. Chizzolini, S. Miotto, F. De Geronimo, G. Paolo, R. Melis, F. Parmegiani, S. Piermarocchi

OS1 - 05  AMNIOTIC MEMBRANE TO REPAIR RETINAL DETACHMENT DUE TO PARAVASCULAR RETINAL BREAKS OVER PATCHY CHORIORETINAL ATROPHY IN PATHOLOGIC MYOPIA.
L. De Angelis, T. Caporossi, S. Rizzo

OS1 - 06  SURGICAL TREATMENT OF PRIMARY RHEGMATOGENOUS RETINAL DETACHMENTS: THE REAL-LIFE EXPERIENCE OF A HIGH-VOLUME CENTRE OVER THE LAST 3 YEARS.

OS1 - 07  “SI OIL RETENTION SUTURE” - IN THE MANAGEMENT OF TOTAL RETINAL DETACHMENT IN APHAKIC PATIENT WITH THE ABSENCE OF NASAL IRIS.
V.D. Dzinic, A. Oros

OS1 - 08  COMPARATIVE ANALYSIS OF RETINAL REATTACHMENT SURGERY WITH OR WITHOUT ILM PEELING TO PREVENT POST-OP MACULAR PUCKER.
M. Forlini, P. Date

OS1 - 09  CHORIORETINAL COLOBOMA ASSOCIATED WITH PEDIATRIC CATARACT AND RETINAL DETACHMENT.
A. Grandinetti

OS1 - 10  VARIATION OF INTRAOCULAR PRESSURES IN EYES WITH DIFFERENT LEVELS OF GAS TAMPONDES DURING TRANSPORT AT DIFFERENT ALTITUDES.
A. Ivanov, M. Dogramaci, K. Bartzelioti, D. Vaideanu-Collins
OS1 - 11  RECTUS MUSCLE TEAR DURING SCLERAL BUCKLE SURGERY.
C. Kim

OS1 - 12  TALE OF A SUBMACULAR PEARL.
V. Kumar, D. Dubey, M. Chandra, P. Chandra, A. Kumar

OS1 - 13  ROLE OF ILM PEELING DURING VITRECTOMY FOR RHEGMATOGENOUS RETINAL DETACHMENT TO PREVENT POSTOPERATIVE EPIRETINAL MEMBRANE: A RANDOMIZED TRIAL.
V. Kumar

OS1 - 14  MICROSCOPE INTEGRATED OPTICAL COHERENCE TOMOGRAPHY-GUIDED AUTOLOGOUS FULL THICKNESS NEUROSENSORY RETINAL AUTOGRRAFT FOR LARGE MACULAR HOLE RELATED TOTAL RETINAL DETACHMENT.
A. Singh, M. Dogra, B. Tigari, R. Singh

OS1 - 15  HUMAN AMNIOTIC MEMBRANE PLUG TO PROMOTE RETINAL BREAKS REPAIR IN RETINAL DETACHMENT WITH LARGE MACULAR TEAR.
B. Pacini, T. Caporossi, S. Rizzo

OS1 - 16  PUBLICATION TRENDS IN PARS PLANA VITRECTOMY IN THE LAST DECADE.
G. Pekel, E. Pekel, E. Cetin

OS1 - 17  OUTCOMES OF SUPRACHOROIDAL HAEMORRHAGE DRAINAGE SURGERY: THE 10-YEAR MANCHESTER EXPERIENCE.
A. Qureshi, A. Jalil, N. Patton, S. Charles, F. Dhawahir-Scala, G. Turner, T. Ivanova

OS1 - 18  AN ENDOSCOPIC APPROACH TO SIMULTANEOUS COMPLEX ANTERIOR PVR PEELING AND INTRASCLERAL IOL FIXATION.
F. Rezende, R. Duval

OS1 - 19  COMPLETE VITRECTOMY WITH ANTERIOR HYALOID DISSECTION.
D. Ruiz Casas, D. Arruabarrena Sanchez

OS1 - 20  RETINAL DISPLACEMENT DETECTED BY RETINAL VESSEL PRINTING ON FUNDUS AUTOFLUORESCENCE IMAGING: PNEUMATIC RETINOPEXY VERSUS PARS PLANA VITRECTOMY - A MULTICENTER STUDY.

OS1 - 21  BILATERAL VITREOUS HEMORRHAGE IN TERSON’S SYNDROME.
S. Scrittori

OS1 - 22  CHANGES OF PHYSICO-CHEMICAL PROPERTIES OF SILICONE OIL ASSOCIATED WITH A RETINAL TAMPONADE.
V. Serhienko
EVALUATION OF HYALOID–RETINAL RELATIONSHIP DURING TRIAMCINOLONE-ASSISTED VITRECTOMY FOR PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT.

D. Sundaram, B. Takkar, P. Venkatesh, R. Chawla, S. Temkar

GLYCERINE ASSISTED VITREORETINAL SURGERY IN DECOMPENSATED OEDEMATOUS CORNEA.

A. Surve, V. Kumar

OCT ANGIOGRAPHY IN RHEGMATOGENOUS RETINAL DETACHMENT.


ORAL PRESENTATIONS

OS1 - 23 EVALUATION OF HYALOID–RETINAL RELATIONSHIP DURING TRIAMCINOLONE-ASSISTED VITRECTOMY FOR PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT.

D. Sundaram, B. Takkar, P. Venkatesh, R. Chawla, S. Temkar

OS1 - 24 GLYCERINE ASSISTED VITREORETINAL SURGERY IN DECOMPENSATED OEDEMATOUS CORNEA.

A. Surve, V. Kumar

OS1 - 25 OCT ANGIOGRAPHY IN RHEGMATOGENOUS RETINAL DETACHMENT.


13:00 - 15:00 FREE PAPERS - MEDICAL 1

ROOM ONICE

CHAIRS: Bressler S., Brucker A., Loewenstein A., Viola F.

OM1 - 01 OCT ANGIOGRAPHY, ULTRA-WIDE-FIELD LASER SCANNING FUNDUS IMAGING AND AUTOFLUORESCENCE FINDINGS IN SUSAC’S SYNDROME: A CASE REPORT.

S.A. Bagaglia, F. Passani, P. Esposti, P. Mittica, C. Mazzotta, M. Fruschelli, N. Lorusso

OM1 - 02 MULTIMODAL IMAGING AND FUNCTIONAL CORRELATION WITH MICROPERIMETRY IN PATIENTS WITH TYPE 2 MACULAR TELANGIECTASIA.

P. Baptista, N. Silva, I. Carneiro, M. João Furtado, M. Lume

OM1 - 03 OPTICAL COHERENCE TOMOGRAPHY AND ANGIOGRAPHY PARAMETERS PREDICTIVE OF VISUAL OUTCOME AFTER ANTI-VEGF THERAPY FOR BRANCH RETINAL VEIN OCCLUSION.


OM1 - 04 OPTICAL COHERENCE TOMOGRAPHY AND ANGIOGRAPHY PARAMETERS PREDICTIVE OF VISUAL OUTCOME AFTER ANTI-VEGF THERAPY FOR CENTRAL RETINAL VEIN OCCLUSION.


OM1 - 05 ULTRA-LOW-MOLECULAR-WEIGHT HEPARIN, FONDAPARINUX, IN RETINAL VEIN OCCLUSIONS.

R.D.J. Steigerwalt, A. Pascarella, M. De Angelis, F. Ciucci, F. Gaudenzi
OM1 - 06  TREATMENT OUTCOMES OF COMBINATION THERAPY WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND LASER PHOTOCOAGULATION IN TYPE 1 ROP AND APROP.
A. Agarwal, P. Sen, P. Bhende, S. Ganesan

OM1 - 07  EFFICACY OF INDIRECT LASER PHOTOCAGULATION IN CASES WITH RETINOPATHY OF PREMATURITY PRESENTING WITH LATE STAGE 3 TURNING INTO STAGE 4A.
M. Al-Feky

OM1 - 08  DIFFUSE BILATERAL SUBACUTE NEURORETINITIS (DBSN).
S. Carrillo Cristancho, P.V. De Miguel Simó, C. Barnes Ruz, E. Cantal Portabella, C. Macià Badia

OM1 - 09  SCLERAL FIXATION OF FLUCINOLONE ACETONIDE IMPLANT IN EYES WITH SEVERE IRIS-LENSES DIAPHRAGM DISRUPTION AND CLINICAL RELEVANT CME.
T. Herold, A. Almarzooqi, S.G. Priglinger, A. Wolf

OM1 - 10  OPHTHALMOLOGICAL APPROACH TO SAVING A LIFE.
P. Kumar, G. Verma, I. Aggarwal, R. Maggon

OM1 - 11  CYTOMEGALOVIRUS RETINITIS IN PEDIATRIC HEMATOPOIETIC STEM CELLS RECIPIENTS.
B. Pershin, A. Smirnova, L. Shelihova, A. Maschan, V. Mahmutov

OM1 - 12  COMBINED THERAPY IN CHOROIDAL NEOVASCULAR MEMBRANE SECONDARY TO MULTIFOCAL CHOROIDITIS: LONG-TERM VISUAL AND ANATOMICAL OUTCOMES.
V. Pirani, P. Pelliccioni, R. Calamita, M. Nicolai, C. Cesari, A. Giovannini, C. Mariotti

OM1 - 13  SUBTHRESHOLD YELLOW MICROPULSE LASER TREATMENT IN A CASE OF UNRESPONSIVE PSEUDOPHAKIC MACULAR EDEMA.
T. Verdina, C. Ferrari, A. Brombin, G.M. Cavallini

OM1 - 14  OCTA AND RETINAL THICKNESS LAYERS FINDINGS IN TYPE 1 DIABETES.
F. Scarinci

OM1 - 15  EVALUATION OF VESSEL MORPHOLOGY TOWARDS THE RETINAL PERIPHERY USING WIDE FIELD OCT ANGIOGRAPHY.
C. Lavia, A. Couturier, P. Mece, M. Nassisi, S. Bonnin, J. Marie Louise, A. Gaudric, R. Tadayoni

OM1 - 16  OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN A PAEDIATRIC POPULATION WITH DIABETES MELLITUS.
L. Diplotti, S. Pignatto, P. Lanzetta

OM1 - 17  RETINAL VASCULAR RESPONSE TO THE HANDGRIP TEST IN TYPE 1 DIABETES USING OCT-ANGIOGRAPHY.
D. Sousa, I. Leal, A. Silva-Herdade, S. Moreira, S. Do Vale, P. Dionísio, L. Abegão Pinto, M. Castanho, C. Marques-Neves

OM1 - 18  INDOCYANINE GREEN ANGIOGRAPHY FOR IDENTIFYING TELANGIECTATIC CAPILLARIES IN DIABETIC MACULAR EDEMA.
OM1 - 19  BASELINE TRIGLYCERIDE-GLUCOSE INDEX PREDICTS PREVALENCE AS WELL AS INCIDENCE OF DIABETIC RETINOPATHY IN ASIANS WITH TYPE 2 DIABETES.
N.K. Bhaskar, X. Zhang, S. Low, T. Subramaniam, S. Lim

OM1 - 20  EVALUATION OF THE EFFECT OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS ON ACTIVE NEOVASCULARIZATION IN CLINICAL PRACTICE IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY.
G. Guzaliya Kudasheva, V. Evgrafov Vladimir

OM1 - 21  PAN-RETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY - IMPACT ON VISUAL FUNCTION.
A. Marta, P.M. Baptista, I. Carneiro, D. José, D. Almeida, A. Ribeiro, I. Barbosa

OM1 - 22  PHOTORECEPTOR DAMAGE IN DIABETIC CHOROIDOPATHY.
M. Palmieri

OM1 - 23  ASSOCIATION OF RETINAL BIOMARKERS AND CHOROIDAL VASCULARITY MARKERS ON OPTICAL COHERENCE TOMOGRAPHY USING BINARIZATION METHOD IN DIABETIC MACULAR EDEMA.
E. Cetin

OM1 - 24  DIABETIC MACULAR OEDEMA: REAL LIFE RESULTS OF INTRAVITREAL INJECTION OF ANTI-VEGF.
P. Corazza, H. Orlans, T. Soomro, S. Yonis

OM1 - 25  EFFICACY AND SAFETY OF INJECTING TRIAMCINOLONE ACETONIDE IN THE SUPRACHOROIDAL SPACE USING CUSTOM MADE NEEDLE FOR DIABETIC MACULAR EDEMA TREATMENT.
A. Marashi

OM1 - 26  ONE-YEAR RESULTS OF MODIFIED TREAT-AND-EXTEND REGIMEN USING AFLIBERCEPT FOR DIABETIC MACULAR EDEMA; VIBIM STUDY.
S.W. Park, E.H. Kim, J.E. Lee

OM1 - 27  ANATOMICAL RESULTS PREDICTORS OF TREATMENT IN PATIENTS WITH DIABETIC MACULAR EDEMA AFTER THE FIRST ANTI-VEGF INJECTION.
D. Petrachkov, D. Arzhukhanov, M. Budzinskaya

OM1 - 28  COST-CONSEQUENCE ANALYSIS OF EXTENDED LOADING DOSE OF ANTI-VEGF TREATMENT IN DIABETIC MACULAR EDEMA PATIENTS.
J.M. Ruiz-Moreno, F. De Andrés-Nogales, I. Oyagüez

OM1 - 29  UNEXPECTED EVENT IN DME THERAPY: CLINICAL BEHAVIOR AND RESULTS.
S. Donati, L. Premoli, C. Metrangolo, M. Abbate, W. Messina, M. Mazzola, C. Azzolini
SATURDAY 8 JUNE

11:00 - 13:00 FREE PAPERS - SURGICAL 2

ROOM ONICE

CHAIRS: Lesnioni G., Nikolakopoulos A., Panozzo G., Schwart S.D.

OS2 - 01 NEGATIVE CORRELATION BETWEEN RETINAL DISPLACEMENT AND GANGLION CELL LAYER THICKNESS CHANGES IN EYES WITH EPIRETINAL MEMBRANE.

P. Loiudice, M. Pellegrini, A. Montesel, M. Figus, M. Nardi, G. Casini

OS2 - 02 25G VITRECTOMY WITH ERM AND MLI PEELING 30 DAYS AFTER DEXAMETHASONE IMPLANT IN PATIENTS WITH MACULAR PUCKER AND DIABETIC RETINOPATHY.

F. Pignatelli, G. Addabbo

OS2 - 03 PREMACULAR HEMORRHAGE.

M. Stamenkovic, V. Jaksic, A. Bajic, B. Vukadinovic, N. Nikitovic, M. Mavija

OS2 - 04 HEADS-UP 3D VISION SYSTEM REDUCES ACUTE PHOTOTOXIC-RELATED AUTOFLUORESCENCE CHANGES AFTER MACULAR SURGERY.

C. La Spina, C. Del Turco, G. D’amico Ricci, D.C. Giobbio, C. Panico

OS2 - 05 AN ANALYSIS OF CAPSULAR FLAPS USED FOR PERSISTENT FTMH.

W. Armin, D. Vogt, S. Priglinger, R. Schumann

OS2 - 06 RETINAL THICKNESS CHANGES AND FOVEA MIGRATION IN EYES WITH IDIOPATHIC MACULAR HOLE AFTER VITRECTOMY WITH HEMI-TEMPORAL INTERNAL LIMITING MEMBRANE PEELING.

J. Kogo, A. Shiono, T. Jujo, H. Takagi

OS2 - 07 EFFECTIVENESS OF SUPERIOR INVERTED INTERNAL LIMITING MEMBRANE (ILM) FLAP IN MACULAR HOLE SURGERY: ANATOMICAL AND FUNCTIONAL OUTCOMES.

M.D.M. Prieto Del Cura, M.J. Crespo Carballes, M. Acebes Garcia, J. Garcia Hinojosa

OS2 - 08 LAMELLAR MACULAR HOLES: WHEN IS SURGERY RECOMMENDED.

R.G. Schumann

OS2 - 09 AN ANALYSIS OF THE RESULTS OF PARON PLANA VITRECTOMY IN THE SURGICAL TREATMENT OF LAMELLAR MACULAR HOLES.

K. Zhogolev, Y. Bayborodov, I. Panova
OS2 - 10 OCRIPLASMIN IN THE TREATMENT OF VITREOMACULAR TRACTION: A META-ANALYSIS OF DOUBLE-BLIND RANDOMIZED CONTROLLED TRIALS BASED ON SUBJECT-LEVEL DATA.
T. Jackson, K. Blot, B. Lescrauwaet, L. Duchateau, J. Haller

OS2 - 11 PULSATILE RETINAL ARTERY MACROANEURYSM POST LASER HYALOIDOTOMY.
K. Srinivasan

OS2 - 12 FIRST IN HUMAN CLINICAL TRIAL OF ROBOT-ASSISTED SUBRETINAL DRUG DELIVERY UNDER LOCAL ANAESTHESIA.
J. Kapetanovic, K. Xue, T.L. Edwards, H.C.M. Meenink, M.J. Beelen, G.J.L. Naus, M.D. De Smet, R.E. Maclaren

OS2 - 13 MICROSCOPE-INTEGRATED INTRAOPERATIVE OPTICAL COHERENCE TOMOGRAPHY-GUIDED INTERNAL LIMITING MEMBRANE PEELING WITH INVERTED ILM FLAP TECHNIQUE FOR MYOPIC TRACTION MACULOPATHY ASSOCIATED RETINAL DETACHMENT: A NOVEL TECHNIQUE.
A.K. Kumar, D. Agarwal, D. Sunder

OS2 - 14 SCLERAL BUCKLING IN THE MANAGEMENT OF RECURRENT RETINA DETACHMENT IN SILICONE OIL FILLED EYES.
R. Giannini, L. Zompatori, T. Mascaro, G. Cuozzo, A. Mauro

OS2 - 15 MYOPIC TRACTION MACULOPATHY: THE NEW ITALIAN STAGING SYSTEM (MISS).
B. Parolini, M. Palmieri, U. Nava

OS2 - 16 SUBRETINAL INJECTION PLATELET-RICH PLASMA FOR HIGHLY MYOPIC FOVEOSCHISIS: TECHNIQUE AND OUTCOM.
V. Zotov

OS2 - 17 VITRECTOMY FOR OPTIC DISC PIT MACULOPATHY.
A. Alkaliby

OS2 - 18 CLINICAL UTILITY OF INTRAOPERATIVE OCT IN VARIOUS OF POSTERIOR SEGMENT PATHOLOGIES.
A. Singh, B. Moharana, B. Tigari, R. Singh

OS2 - 19 SURGICAL CHALLENGES OF BILATERAL RHEGMATOGENOUS ON TRACTIONAL RETINAL DETACHMENTS IN A MALAY PATIENT WITH PROLIFERATIVE DIABETIC RETINOPATHY.
M.B. Bastion

OS2 - 20 DIABETIC NIGHTMARE.
A. La Mantia, A. Pioppo

OS2 - 21 EFFICACY OF INTRAOPERATIVE RANIBIZUMAB INJECTION WITH LONG-ACTING GAS INFUSION ON RECURRENCE OF VITREOUS HEMORRHAGE AFTER DIABETIC VITRECTOMY.
S. Ozen
OS2 - 22  PSEUDOPHAKIA PROTECTS AGAINST FELLOW EYE DIABETIC VITREOUS HAEMORRHAGE.
    P. Scollo, Y. Yang, C. Svasti-Salee, N. Dervenis, R.S.B. Newsom, L. Sullivan, D. Hornan

OS2 - 23  PARS PLANA VITRECTOMY ENDORESECTION FOR INTRAOCULAR MEDULLOEPITHELIOMA.
    G. Pieretti, S. Rizzo, G. Vicini, C. Nicolosi, D. Massi, C. Mazzini

OS2 - 24  ENDORESECTION AFTER A RU106 BRACHYTHERAPY FAILURE.
    M.i. Relimpio Lopez, A. Alcantara Santillana, M.j. Diaz Granda, L. Coca Gutierrez, F. Espejo Arjona, B. Dominguez Garcia

SUNDAY 9 JUNE

08:00 - 09:30 FREE PAPERS - SURGICAL 3

ROOM VERDE

CHAIRS: Binder S., Kadonosono K., Marullo M., Micelli Ferrari T., Tognetto D.

OS3 - 01  CHALLENGING CASES OF INTRA-OCULAR FOREIGN BODY REMOVAL.
    M. Bansal

OS3 - 02  A RUPTURED GLOBE WITH POST-TRAUMATIC CLOSED RETINAL DETACHMENT AND IOL LUXATION.
    G. Besozzi, M.c. Costa, G. Nitti, A. Mocellin

OS3 - 03  EYE INJURIES IN AN ITALIAN URBAN POPULATION-STUDY II: THE TEN-YEAR REPORT OF THE EYE EMERGENCY DEPARTMENT OF TORINO.
    C. Del Turco, C. La Spina, E. Belcastro, C. Panico, G. D’amico Ricci

OS3 - 04  VITRECTOMY IN PATIENTS WITH SCLERAL RUPTURE AFTER BLUNT EYE INJURIES.
    N. Grubnyk, T. Krasnovid

OS3 - 05  LENS LUXATION INTO THE VITREOUS HUMOUR.
    S.I. Popescu, O. Musat, C. Cernat

OS3 - 06  REMOVAL OF IOFB THROUGH ANTERIOR CHAMBER USING VITRECTOMY PROBE ONLY.
    M.A.T. Tawfik

OS3 - 07  THE SURGICAL REPAIR OF A PENETRATING OCULAR INJURY FROM A WRITING INSTRUMENT IN A CHILD.
    A. Qureshi, L. Fu, A. Jalil

OS3 - 08  USES OF BENT NEEDLE IN VITREORETINAL SURGERY.
    A. Habib
**OS3 - 09** EFFECTIVENESS OF LASER VITREOLYSIS FOR VITREOUS FLOATERS IN POSTERIOR VITREOUS DETACHMENT IN MALAYSIAN PATIENTS: A PILOT STUDY.

M.B. Bastion, S. Syed Zulkifli, M. Mushawiaht, W. Goh

**OS3 - 10** TAILORED APPROACHES IN SUB-HYALOID HEMORRHAGES: RATIONALE AND OUTCOMES.

M. Chizzolini, S. Miotto, G. Paolo, F.F. De Geronimo, S. Piermarocchi

**OS3 - 11** A NEW TECHNIQUE FOR REMOVAL OF MIRAGEL SCLERAL BUCKLE EXPLANTS: SIMPLE ASPIRATION WITH A FRAZIER SUCTION CANNULA.

E. Bertelli, P. Santorum, M.L. De Vitto

**OS3 - 12** TISSUE PLASMINOGEN ACTIVATOR AND AIR INJECTION FOR MANAGEMENT OF SUBMACULAR HEMORRHAGE.

A. Habib, M. Mekkawy, I. Mohamed, H. Hassan

**OS3 - 13** SCLERAL FIXATION IOLS: 3-PIECE IOL WITH INTRASCERAL FIXATION OF THE APTICS VS A NEW SPECIFICALLY DESIGNED IOL. A COMPARATIVE STUDY.

M.G. Cereda, I. D’agostino, S. De Angelis, F. Zicarelli, S. Parrulli, F. Bottoni, G. Staurenghi

**OS3 - 14** SCLERAL FIXATION OF INTRAOCULAR LENS USING EXTRA OCULAR NEEDLE INSERTION TECHNIQUE (X-NIT) : CLINICAL OUTCOMES AND SAFETY PROFILE.

V.V. Koundanya, B. Sarma

**OS3 - 15** MODIFIED APPROACH IN MANAGEMENT OF SUBMACULAR HEMORRHAGE SECONDARY TO POLYPOIDAL CHOROIDAL VASCULOPATHY- A NOVEL TECHNIQUE.

A.K. Kumar, A. Kumar, D. Agarwal, L. Rambarki

**OS3 - 16** A NOVEL TECHNIQUE OF MANAGEMENT OF POSTERIOR SCLERAL PERFORATION USING AMNIOTIC MEMBRANE GRAFT.

R. Kurumkatil, H. Trehan

**OS3 - 17** AUTOLOGOUS RETINAL TRANSPLANT FOR RHEGматOGENOUS RETINAL DETACHMENT WITH LARGE FULL THICKNESS MACULAR HOLE.

A. La Mantia, A. Pioppo

**OS3 - 18** SEMIAUTOMATED DELIVERY OF SUBRETINAL DRUGS BY VISCOUS FLUID INJECTOR SYSTEM – MODIFIED TECHNIQUE, SUITABLE FOR MYOPIC EYES.

H. Proença, P. Magro

**OS3 - 19** VITRECTOMY FOR ENDOPHTHALMITIS IN EYES WITH OSTEO-KERATOPROSTHESIS.

F. Vilaplana, J. Nadal, J. Temprano, G. Julio, M. Olivera, R. Barraquer
SURGICAL APPROACH FOR REMOVAL OF A SUBFOVEAL DENSIRON 68 BUBBLE IN A CASE OF RECURRENT RETINAL DETACHMENT.
A. Savastano, C. Nicolosi, G. Vicini, S. Rizzo

SUB-RETINAL AIR INJECTION TO REMOVE TRAPPED PFCL BUBBLES
U. Lorenzi, M. Muraine

CORNEAL COMPLICATIONS AFTER PARS PLANA VITRECTOMY.
R. Vignapiano, E. Favuzza, M. Cennamo, R. Mencucci

08:00 - 10:00 FREE PAPERS - MEDICAL 2
ROOM ONICE
CHAIRS: Augustin A., Lanzetta P., MacLaren R., Zweifel S.

OM2 - 01 ROLE OF ULTRA-WIDE FIELD IMAGING IN PATIENTS OF EALES’ DISEASE.
A. Agarwal, J. Biswas

OM2 - 02 NAVILAS ABILITY AND USEFULNESS TO RECOGNIZE RETINAL TEARS IN THE FAR PERIPHERY AND TO EVIDENCE TREATED LESIONS AFTER THE LASER RETINOPEXY PROCEDURE.
E. Di Carlo, A. Augustin

OM2 - 03 RETINAL PIGMENT EPITHELIUM APERTURES AS A LATE COMPLICATION OF LONGSTANDING SEROUS PIGMENT EPITHELIUM DETACHMENTS IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
C. Iovino, J. Chhablani, D. Parameswarappa, M. Pellegrini, G. Giannaccare, E. Peiretti

OM2 - 04 SOLITARY CIRCUMSCRIBED RETINAL ASTROCYTIC PROLIFERATION IMAGED WITH OCT ANGIOGRAPHY.
J. Kovach

OM2 - 05 MACULAR FINDINGS IN CHILDREN WITH SICKLE CELL DISEASE: AN OCT ANGIOGRAPHY STUDY.
D. Lopes, T. Loureiro, R. Carreira, A. Vide Escada, I. Machado, N. Campos

OM2 - 06 OCT ANGIOGRAPHY FUNDUS PATTERNS IN A PEDIATRIC POPULATION WITH SICKLE CELL ANEMIA.
S. Pignatto, L. Grego, F. Rizzetto, G. Beltrame, P. Lanzetta

OM2 - 07 MULTIMODAL IMAGING IN UNILATERAL ACUTE IDIOPATHIC MACULOPATHY: A CASE REPORT.
M. Romdhane, N. Abroug, S. Zina, M. Bouguerra, B. Jelliti, M. Khairallah

OM2 - 08 OCT ANGIOGRAPHY: NEOVASCULARIZATION INCIDENCE IN CSC.
M.C.S. Savastano
OM2 - 09  CORRELATION OF DISTINCT FUNDUS AUTOFLUORESCENCE FEATURES WITH DISRUPTION OF THE OVERLYING ELLIPSOID ZONE IN CHOROIDEREMIA.
M. Stevanovic, J. Cehajic Kapetanovic, J.K. Jolly, R.e. Maclaren

OM2 - 10  IMAGING CHARACTERISTICS OF DARK AREAS ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND INDOCYANINE GREEN ANGIOGRAPHY - CLINICAL INSIGHTS WITH ILLUSTRATIONS.
D. Sundaram, R. Chawla, S. Agarwal, N. Hasan

OM2 - 11  DETECTION OF AGE-RELATED MACULAR DEGENERATION USING OCT-A AND ARTIFICIAL INTELLIGENCE.
E. Vaghefi, M. Lin, S. Hill, D. Squirrell

OM2 - 12  CHOROIDAL AND RETINAL LAYER THICKNESS ALTERATIONS IN EARLY AGE RELATED MACULAR DEGENERATION ASSOCIATED WITH SUBRETINAL DRUSENOID DEPOSITS.
S. Abdolrahimzadeh, V. Fenicia

OM2 - 13  PREVALENCE AND INCIDENCE OF AGE-RELATED MACULAR DEGENERATION IN PATIENTS ATTENDING DIABETIC RETINOPATHY SCREENING.
E. Lourenco, D. Parry, T. Criddle, G. Czanner, S. Harding, A. Alshukri, P. Burgess

OM2 - 14  CHOROIDAL NEOVASCULARISATION “MASQUERADING” AS A MASQUERADE SYNDROME.
I. Papandreou, K. Tourmouzis

OM2 - 15  SHORT-TERM CHOROIDAL VASCULAR CHANGES AFTER AFLIBERCEPT THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
M. Pellegrini, F. Bernabei, G. Casini, P. Loiudice, G. Giannaccare

OM2 - 16  AGE RELATED MACULAR DEGENERATION: LONG TERMS RESULTS FROM REAL WORLD DATA.
P. Corazza, T. Soomro, H. Orlans, S. Younis

OM2 - 17  A NEW MODEL FOR MANAGEMENT OF INTRAVITREAL INJECTION (IVI): BARI POLICLINICO REAL-WORLD EXPERIENCE.
M.O. Grassi, C. Furino, N. Recchimurzo, G. Alessio

OM2 - 18  OCT-A FEATURES OF SUBRETINAL FIBROSIS SECONDARY TO MYOPIC NEOVASCULARIZATION.

OM2 - 19  INTRAVITREAL USE OF BONE MARROW MONONUCLEAR FRACTION CONTAINING CD34+ STEM CELLS IN PATIENTS WITH ATROPHIC AGE-RELATED MACULAR DEGENERATION.
R.C. Siqueira

OM2 - 21  ULTRA WIDE FIELD IMAGING OF CHOROIDAL DYSTROPHIES.
V. Kumar
OM2 - 22  NATURAL HISTORY OF THE PROGRESSION OF RPGR-ASSOCIATED X-LINKED RETINITIS PIGMENTOSA (XOLARIS) STUDY: CROSS-SECTIONAL ANALYSIS OF BASELINE CHARACTERISTICS.
M. Menghini, D. Birch, C. Boon, J. Duncan, M. Fischer, F. Holz, C. Hoyng, K. Khan, I. Meunier, T. Ong, M. Pennesi, E. Sankila, R. Maclaren

OM2 - 23  NEAR-INFRARED AUTOFLUORESCENCE IN YOUNG CHOROIDEREMIA (CHM) PATIENTS.

OM2 - 24  FILTRATION OF SHORT WAVELENGTH LIGHT PROVIDES THERAPEUTIC BENEFIT IN A MOUSE MODEL OF DOMINANT RETINITIS PIGMENTOSA.
H. Orlans, J. Merrill, A. Barnard, P. Charbel Issa, S. Peirson, R. Maclaren

OM2 - 25  MORPHO-FUNCTIONAL ANALYSIS OF STARGARDT DISEASE FOR READING.
P. Sasso, A. Scupola, V. Silvestri, F. Amore, E. Abed, L. Calandriello, G. Grimaldi, A. Caporossi

OM2 - 26  OCTA-BASED IDENTIFICATION OF DIFFERENT VASCULAR PATTERNS IN STARGARDT DISEASE.
A. Arrigo, F. Romano, E. Aragona, C. Di Nunzio, A. Sperti, F. Bandello, M. battaglia Parodi

OM2 - 27  DESCRIPTION OF MACULAR MORPHOLOGY IN PATIENTS WITH RETINITIS PIGMENTOSA USING SPECTRAL DOMAIN OCT.

OM2 - 28  FOUR YEAR RESULTS OF INTRA ARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA FROM A TERTIARY CARE CENTRE.
A. Agarwal, P. Chatterjee, M. Saravanan, R. Ravikumar, P. Rishi

OM2 - 29  DIFFERENTIAL DIAGNOSIS BETWEEN CHOROIDAL NEVUS AND MELANOMA BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.
C. Garcia Arumi, F. Peralta, M. Bove, J. Garcia Arumi

OM2 - 30  OCT CHANGES IN PERI-TUMOUR NORMAL RETINA FOLLOWING RUTHENIUM-106 AND PROTON BEAM RADIOTHERAPY FOR UVEAL MELANOMA.
R. Hussain, F. Heussen, S. Quereshi, H. Heimann

OM2 - 31  AURORA BOREALIS AND STRING OF PEARLS IN VITREORETINAL LYMPHOMA: PATTERNS OF VITREOUS HAZE.
A. Marchese, E. Miserocchi, C. Giuffre’, M. Cicinelli, G. Querques, G. Modorati, F. Bandello
POSTER PRESENTATIONS

P - 01 CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND COMBINED FLUORESCEIN AND
INDOCYANINE GREEN ANGIOGRAPHY FOR THE DIAGNOSIS OF DIFFERENT TYPES OF CHOROIDAL NEOVASCULARIZATION
IN PATIENTS WITH EXUDATIVE AMD. A MULTIMODAL IMAGE ANALYSIS.
M. Fernández Rodríguez, P. Santos Ramos, P. Almuiña Varela, M. Rodríguez Cid, F. Gomez-Ulla De Irazazabal

P - 02 S.T.A.R. SQUESTIONNAIRE AS A METHOD OF IDENTIFICATION PATIENT’S RISK OF AMD.
N. Malachkova, T. Kozlova, K. Radega, Y. Prus

P - 03 IMPROVING THE METHODS OF CONSERVATIVE TREATMENT OF THE DRY FORM OF INVOLUTIONAL MACULAR
DEGENERATION.
N. Yangieva, F. Mirbabaeva, S. Agzamova

P - 04 CYSTOID MACULAR EDEMA WITH PANUVEITIS AND SCLEROMALACIA TREATED WITH OZURDEX IN WEGENER’S
GRANULOMATOSIS: 6 MONTH FOLLOW UP.
M. Sauza, M. Puerto, R. Washington

P - 05 CHOROIDEREMIA AND CHOROIDEREMIA CARRIER - CASE STUDY.
M. Ratkovic, A. Pidro

P - 06 AP-ROP TREATMENT: VITREOUS SYNERESIS AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB.
I. Akkoyun, Z. Ersoy, G. Yilmaz, O. Turan

P - 07 A CASE OF ORBITAL AND CHOROIDAL PLASMACYTOMA IN RECURRENT MULTIPLE MYELOMA.
C. Choi, J. Choi, J. Jeong

P - 08 VITRECTOMY WITH SILICONE OIL TAMPONADE FOR METASTATIC BREAST ADENOCARCINOMA TO THE CHOROID. IS THERE
RADIATION ATTENUATION EFFECT TO THE SILICONE OIL? CASE REPORT AND LITERATURE REVIEW.
A. Alkaliby

P - 09 INTRAVITREOUS TISSUE PLASMINOGEN ACTIVATOR WITH PNEUMATIC DISPLACEMENT FOR SUBMACULAR HAEMORRHAGE -
A YEAR IN REVIEW.
J.B. Braga, F. Neves, P. Sepúlveda, M. Bilhoto
P - 10  CHANGES IN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND DISEASE ACTIVITY IN TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.
H. Cho, J. Han, S. Park, D. Kang, J. Kim

P - 11  INITIAL RESULTS OF RESVERATROL-BASED NUTRITIONAL SUPPLEMENT IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION.
I. Gourgouli, D. Gourgouli, C. Papadopoulou, S. Spai

P - 12  CASE REPORT OF A PATIENT WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH RESVERATROL BASED DIETARY SUPPLEMENT.
I. Gourgouli, C. Papadopoulou, S. Spai

P - 13  DEPRESSION AND ANXIETY OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION ACCORDING TO RELATED FACTORS.
J.Y. Lee, D.Y. Kim, J.Y. Kim

P - 14  EVALUATION OF INTRAOPERATIVE SLOW-RELEASE DEXAMETHASONE IMPLANT COMBINED WITH IDIOPATHIC EPIRETINAL MEMBRANE REMOVAL: PROSPECTIVE STUDY.
A. Bitossi, A. Savastano, L. Vannozzi, F. Giansanti, T. Caporossi, F. Barca, G. Virgili, M.C. Savastano, S. Rizzo

P - 15  AFLIBERCEPT, RANIBIZUMAB AND BEVACIZUMAB FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION USING VARIABLE AND MONTHLY DOSING REGIMES: A LITERATURE REVIEW AND COST ANALYSIS.
S. Rufai, T. Rufai, M. Logendran

P - 16  THE EFFECT OF TRICOR ON THE OCULAR BLOOD FLOW IN PATIENTS WITH THE DRY FORM OF AGE-RELATED MACULAR DEGENERATION.
N. Yangieva, D. Tuychibaeva

P - 17  VISUAL REHABILITATION WITH RETIMAX VISION TRAINER IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION: A CASE-SERIES.
T. Verdina, S. Piaggi, R. Peschiera, V. Russolillo, G.M. Cavallini

P - 18  COMPARISON OF HALF-TIME AND HALF-IRRADIANCE PHOTODYNAMIC THERAPY IN NON-RESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
| P - 19 | AN UNUSUAL CASE OF CENTRAL SEROUS CHORIORETINOPATHY AND RECURRENCE OF POLYPOIDAL CHOROIDAL VASCULOPATHY IN POSTMENOPAUSAL WOMEN RECEIVING HORMONE REPLACEMENT THERAPY.  
K.H. Mun, J.Y. Jang |
| P - 20 | LONG-TERM RESULTS OF HALF-FLUENCE PDT IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY (CSC).  
| P - 21 | MACULAR HOLE PROGRESSION FOLLOWING ND:YAG LASER POSTERIOR CAPSULOTOMY.  
P. Dervenis, N. Dervenis |
| P - 22 | EYE INVOLVEMENT IN A CASE OF DEGENERATIVE RETINOSCHISIS: A CASE REPORT.  
P. Dervenis, N. Dervenis |
| P - 23 | THE OCTA SIGNS THAT CAN REASONABLY INDUCE TO STOP ANTI-VEGF THERAPY IN AMD.  
S. Brogelli, M. Scrivanti |
| P - 24 | CLINICAL CHARACTERISTICS OF SPONTANEOUS MACULAR HOLE CLOSURE OBSERVED BY SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY.  
M. Kimura, K. Okuda, H. Yamada, K. Takahashi |
| P - 25 | COMPARATIVE CHARACTERISTIC OF MAGNETIC PROPERTIES OF TIPS 25-GAUGE FOR PERMANENT EYE MAGNET.  
A. Kulikov, S. Churashov, A. Mikhin, E. Nikolaenko |
| P - 26 | GLOBAL PREVALENCE AND MAJOR RISK FACTORS OF DIABETIC RETINOPATHY.  
D. Andre |
| P - 27 | STUDY TO EVALUATE THE ASSOCIATION OF VITAMIN D LEVELS WITH SEVERITY OF DIABETIC RETINOPATHY.  
L. Lakshmikanth |
| P - 28 | LONGITUDINAL CHANGES IN THE PERIPAPILLARY RETINAL NERVE FIBER LAYER THICKNESS OF DIABETIC PATIENTS: A 3-YEAR PROSPECTIVE OBSERVATIONAL STUDY.  
H.B. Lim, W.H. Lee, J.Y. Kim |
| P - 29 | COMBINED CATARACT SURGERY WITH 25-GAUGE HIGH-SPEED PARS PLANA VITRECTOMY: RESULTS FROM A PROSPECTIVE STUDY.  
| P - 30 | DEVELOPMENT AND PROGRESSION OF RETINOPATHY AND ASSOCIATED RISK FACTORS IN TYPE 1 DIABETIC PATIENTS: A 15-YEAR FOLLOW-UP STUDY.  
M. Tomic, R. Vrabec, S. Ljubic, T. Bulum |
P - 31 OBESITY - A RISK FACTOR FOR DIABETIC RETINOPATHY IN TYPE 2 DIABETES.
R. Vrabec, M. Tomic, S. Ljubic, T. Bulum

P - 32 COMPARISON BETWEEN FIXED AND VARIABLE POWERS OF SUB_THRESHOLD YELLOW MICROPULSE LASER FOR DIABETIC MACULAR EDEMA.

P - 33 DEXAMETHASONE IMPLANT FOR CHRONIC DIABETIC MACULAR EDEMA RESISTANT TO INTRAVITREAL BEVACIZUMAB INJECTION.
Y. Kim, H. Park, H. Kim, J. Kim

P - 34 CHARACTERISTICS OF DIABETIC MACULAR EDEMA PATIENTS WITH SEROUS RETINAL DETACHMENT.
J. Kwon

P - 35 SHORT-TERM CLINICAL OUTCOME OF INTRAVITREAL AFLIBERCEPT INJECTION FOR DIABETIC MACULAR EDEMA.
S. Park, Y. Seong Won

P - 36 SIGNIFICANT CHANGE OF THE CHOROID IN THE EYES WITH OCULAR ISCHEMIC SYNDROME AND SYMPTOMATIC CAROTID ARTERY STENOSIS.
H.M. Kang, J.H. Choi, S.J. Lee

P - 37 PERIPAPILLARY MICROVASCULAR CHANGES IN THE FELLOW EYES OF PATIENTS WITH UNILATERAL RETINAL VEIN OCCLUSION: AN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY STUDY.
J.Y. Kim

P - 38 TOMOGRAPHIC AND ELECTRON MICROSCOPY FINDINGS OF LAMELLAR HOLE ASSOCIATED EPIRETINAL PROLIFERATION IN CHOROIDEREMIA.

P - 39 S100 MARKER IN THE DIAGNOSIS OF ATHEROSCLEROTIC ANGIOPATHY.
D. Makhkamova

P - 40 REPORT ON A CASE OF SOLITARY CAPILLARY DILATION WITH FEATURES OF PEVAC AND TYPE I MACULAR TELANGIECTASIA.
M. Mambretti, C. Mansoldo, G. Marchini

P - 41 ELECTROGENESIS OF THE RETINA AFTER VITRECTOMY FOR THE PRIMARY FULL-THICKNESS MACULAR HOLE.
E. Nikolaenko, A. Kulikov
P - 42  SPONTANEOUS RESOLUTION OF INTRARETINAL FLUID DUE TO OPTIC DISK PIT.
I. Papandreou, A. Komninou

P - 43  INTRAVITREAL BEVACIZUMAB IN TREATMENT OF PROLIFERATIVE TYPE 2 JUXTAFOVEAL TELANGIECTASIA.
I. Perente

P - 44  LENS-SPARING VITRECTOMY IN PREDOMINATELY POSTERIOR PERSISTENT FETAL VASCULATURE WITHOUT AXIAL LENS
OPACIFICATION.
N. Pastora, J. Peralta, J. Garcia-Hinojosa

P - 45  VISUAL IMPROVEMENT IN A PATIENT WITH PARACENTRAL ACUTE MIDDLE MACULOPATHY TREATED WITH PROSTAGLANDIN E1.
R.D. Steigerwalt

P - 46  EVALUATION OF ANTIHYPERTENSIVE EFFECTIVENESS OF TAFLUPROST IN THE CONTEXT OF CHANGES IN THE IMMUNE AND
BIOCHEMICAL PARAMETERS OF PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA.
D. Tuychibaeva, N. Yangieva

P - 47  THE ANTI-ANGIOGENIC EFFECT OF ANTHOCYANIN OLGOMER IN A MOUSE MODEL OF RETINOPATHY OF PREMATURITY.
S. Kim, K. Kang

P - 48  UTILIZATION A LONG ALTERNATIVE FLAP IN REOPERATION FOR AN OPEN LARGE MACULAR HOLE FOLLOWING INTERNAL
LIMITING MEMBRANE PEELING USING A FLAP TECHNIQUE - A CASE REPORT.
L. Prochazkova, M. Zavorkova

P - 49  UNILATERAL TRANSIENT VISION LOSS FOLLOWING BILATERAL INTRAVITREAL Ocriplasmin- CASE REPORT WITH TWO
YEARS FOLLOW UP.
H. Proença, F. Pinto, F. Campos, S. Vaz-Pereira

P - 50  REMOTE ANATOMO-FUNCTIONAL MONITORING OF RESULTS OF LASER TREATMENT OF AN AGGRESSIVE FORM
OF RETINOPATHY OF PREMATURITY.
M. Pshenichnov, O. Kolenko

P - 51  PAEDIATRIC ENDOGENOUS ENDOPHTHALMITIS SECONDARY TO NEISSERIA MENINGITIDIS REQUIRING URGENT
PARS PLANA VITRECTOMY.
A. Qureshi, J. Ashworth, T. Ivanova

P - 52  OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN CHILDREN WITH LEBER-COATS DISEASE.
A. Turtoro, M. Fortunato, G. Cennamo
P - 53  Efficacy of the Inverted Internal Limiting Membrane Flap Technique with Perfluorocarbon Liquid-Mediated Selective Staining for Large Macular Hole Repair.  
H. Ra

P - 54  Results of Vitrector as Vertical Scissors in 27 Gauge Vitrectomy for Diabetic Vitreous Haemorrhage (VH) and Tractional Retinal Detachment (TRD).  
R. Rahman, K. Soliman

P - 55  Possibilities of Using OCT-Angiography to Assess Retinal Microvascular Changes in Diabetes Mellitus.  
N. Yangieva, S. Agzamova, F. Mirbabaeva

P - 56  A Case Series of Sub-ILM (Internal Limiting Membrane) Hemorrhages and Their Evolution - When to Intervene?  
N.Y. Gan

P - 57  Tomography Features of Retinal Morphology Changes in Patients with Type II Diabetic Mellitus Depending on the Scleral Lamina Cribrosa Thickness.  
M. Karlychuk, P. Bezditko, S. Pinchuk

M. Romdhane, N. Abroug, I. Ksiaa, I. Sellem, B. Jelliti, M. Khairallah

P - 50  Retinal Tears Associated with Ocular Inflammatory Conditions.  
M. Romdhane, N. Abroug, M. Abdelaziz, H. Ben Amor, S. Attia, M. Khairallah

P - 60  Age Related Changes in the Macular Vessel and Perfusion Densities on OCTA: A Normative Data.  
A. Markan, A. Pujari, R. Chawla, A. Kumar, S. Azad

P - 61  Fundus Auto-Fluorescence Appearance in Early Onset Sub-Retinal Deposits.  
M. Mavija, V. Jaksic, M. Stamenkovic

P - 62  Observation of Healing of Macular Holes by Directional OCT and Adaptative Optics Imaging Reveals Misorientation of Parafoveal Photoreceptors.  
J. Villaret, L. Finocchio, A. Sodi, S. Rizzo, M. Paques

P - 63  HLA-B27 Related Exudative Retinal Detachment in Ankylosing Spondylitis- A Case Report.  
T. Chiu, H.C. Lin
P - 64 THE ANTI-INFLAMMATORY EFFECT OF TECTORIGENIN IN A MOUSE EXPERIMENTAL AUTOIMMUNE UVEITIS (EAU) MODEL.
K. Kang, S. Kim

P - 65 RELIABILITY OF MICROPERIMETRY IN PATIENTS WITH X-LINKED RPGR RETINITIS PIGMENTOSA AND CHOROIDERE.
A. Davies, A. Nanda, R. Maclaren

P - 66 NON-IDENTICAL MONOZYGOTIC TWINS WITH RPGR-ASSOCIATED RETINITIS PIGMENTOSA.
A. Nanda, P. Clouston, R. Maclaren

P - 67 FUNDUS ALBIPUNCTATUS DIAGNOSED IN A 51-YEAR-OLD PATIENT.
N. Silva, I. Carneiro, A. Marta, M. Furtado, M. Lume

P - 68 MACULAR VESSEL DENSITY OCTA ANALYSIS IN PATIENTS AFFECTED BY RETINITIS PIGMENTOSA AND MORPHOFUNCTIONAL CORRELATION.
P. Corazza, P. Cirafici, V. Testa, H. Orlans, M. Berisso, C.E. Traverso, M. Nicolò

P - 69 VISUAL OUTCOMES AND POSTOPERATIVE COMPLICATIONS OF COMBINED 25 GAUGE TRANSCONJUNCTIVAL SUTURELESS VITRECTOMY AND GLUED IOL IN CASES OF SUBLUXATED OR DISLOCATED IOLS WITH DEFICIENT CAPSULE.
G. Tsanaktsidis, S. Ly

P - 70 POST-VITRECTOMY ENDOPHTHALMITIS.
G. Vecchione, M. Loffredo

P - 71 SUCCESSFUL TREATMENT OF A LARGE CHOROIDAL MELANOMA IN A YOUNG PATIENT WITH TRANSVITREAL ENDORESECTION COMBINED WITH ADJUVANT RUTHERNIUM BRACHYTHERAPY.
S. Rizzo, G. Vicini, G. Pieretti, C. Nicolosi, C. Mazzini

P - 72 DEEPLY PIGMENTED CLUMPS AT FOVEA: A NOVEL CLINICAL FIND IN FAMILIAL EXUDATIVE VITREO-RETINOPATHY (FEVR).
C.H. Vyas, V. Kadri

P - 73 LOW LUMINANCE AND LOW CONTRAST VISUAL ACUITY AS POTENTIAL OUTCOME MEASURES IN CHOROIDEREMIA CLINICAL TRIALS.
L. Wood, J. Jolly, J. Kapetanovic, C. Andrews, R. Maclaren

P - 74 BILATERAL AND MULTIFOCAL RETINAL ASTROCYTIC HAMARTOMA IN TUBEROUS SCLEROSIS COMPLEX.
N. Silva, P. Baptista, M. Araújo, M. Furtado, M. Lume
COMBINATION OF PNEUMATIC VITREOLYSIS WITH PHACOEMULSIFICATION IN A PATIENT WITH CATARACT AND VITREOMACULAR TRACTION.

P. Zamytskiy, A. Zolotarev, D. Petrachkov, I. Kazakov, E. Miroshnichenko

APPLICATIONS OF IMAGE PROCESSING TECHNIQUES FOR RETINA EYE-FUNDUS IMAGES. SOME MACHINE LEARNING TECHNIQUES APPLIED TO AUTOMATIC DETECTION OF DISEASES FROM RETINA EYE-FUNDUS IMAGES.

O. Vascan, M. Weingart

MACULAR PIGMENTARY CHANGES DUE TO RETINAL HEMORRHAGES IN CHILDREN WITH RETINOPATHY OF PREMATURITY.

M. Mrugacz, R. Antosiuk
<table>
<thead>
<tr>
<th>EXHIBITORS LIST</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AKTIVE</td>
<td>F1</td>
<td></td>
</tr>
<tr>
<td>AL. CHI. MI. A.</td>
<td>E</td>
<td></td>
</tr>
<tr>
<td>ALCON</td>
<td>11 + 12</td>
<td></td>
</tr>
<tr>
<td>ALFA INTES</td>
<td></td>
<td>S + T</td>
</tr>
<tr>
<td>ALLERGAN PHARMACEUTICALS</td>
<td></td>
<td>17 + 18</td>
</tr>
<tr>
<td>Bausch + Lomb</td>
<td>9 + 10</td>
<td></td>
</tr>
<tr>
<td>Bayer</td>
<td></td>
<td>G + H + L + K</td>
</tr>
<tr>
<td>Blue Eye</td>
<td></td>
<td>DESK 10</td>
</tr>
<tr>
<td>Bryn Mawr</td>
<td></td>
<td>DESK 13</td>
</tr>
<tr>
<td>Communications</td>
<td></td>
<td>Ground Floor - Entrance</td>
</tr>
<tr>
<td>C.M.S. Calderaro Medical Service</td>
<td>1 + 2 + 3</td>
<td></td>
</tr>
<tr>
<td>C.S.O. New Tech</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nikon Instruments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compagnia Italiana Ofthalmologica</td>
<td>DESK 2</td>
<td></td>
</tr>
<tr>
<td>Diopsys</td>
<td></td>
<td>M</td>
</tr>
<tr>
<td>Dorc</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td>E. Janach</td>
<td></td>
<td>13</td>
</tr>
<tr>
<td>Ellegi Medical Optics</td>
<td>J1</td>
<td></td>
</tr>
<tr>
<td>Esaso</td>
<td></td>
<td>DESK 11</td>
</tr>
<tr>
<td>Eye Doctor</td>
<td></td>
<td>DESK 5</td>
</tr>
<tr>
<td>Fimas</td>
<td></td>
<td>DESK 12</td>
</tr>
<tr>
<td>Geuder / Alfa Instruments</td>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>Hoya Group</td>
<td></td>
<td>HOSPITALITY SUITE Room 101 - Floor +1</td>
</tr>
<tr>
<td>Johnson &amp; Johnson Vision</td>
<td></td>
<td>DESK 1</td>
</tr>
<tr>
<td>Leica Microsystems</td>
<td></td>
<td>O</td>
</tr>
<tr>
<td>M.S. Medical Service</td>
<td></td>
<td>DESK 6</td>
</tr>
<tr>
<td>Medivis</td>
<td></td>
<td>DESK 9</td>
</tr>
<tr>
<td>Medone Surgical</td>
<td></td>
<td>I</td>
</tr>
<tr>
<td>Nidek Medical</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Novartis Pharma</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>NTC Italia</td>
<td></td>
<td>14</td>
</tr>
<tr>
<td>Oculus Optikgeräte</td>
<td></td>
<td>P + U</td>
</tr>
<tr>
<td>Offhealth</td>
<td></td>
<td>DESK 7</td>
</tr>
<tr>
<td>Ofthalmedica</td>
<td></td>
<td>DESK 8</td>
</tr>
<tr>
<td>Omikron Italia</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Optikon 2000</td>
<td></td>
<td>A + B</td>
</tr>
<tr>
<td>Oxurion</td>
<td></td>
<td>W</td>
</tr>
<tr>
<td>Polifarma</td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Polyoptalmica, New</td>
<td></td>
<td>V</td>
</tr>
<tr>
<td>Second Sight Medical Products</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Sifi</td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>Sooft Italia</td>
<td></td>
<td>R</td>
</tr>
<tr>
<td>Thea Farma</td>
<td></td>
<td>J2</td>
</tr>
<tr>
<td>Vedi Vision / Fimas per Heidelberg</td>
<td>F2</td>
<td></td>
</tr>
<tr>
<td>Vitreq</td>
<td></td>
<td>C + D</td>
</tr>
<tr>
<td>Wisepress</td>
<td></td>
<td>DESKS 3 + 4</td>
</tr>
<tr>
<td>Zeiss</td>
<td></td>
<td>6 + 7 + 8</td>
</tr>
</tbody>
</table>
CONGRESS VENUE

VILLA VITTORIA
- REGISTRATION AREA
- AUDITORIUM
- MEETING ROOMS: VERDE, ONICE, 9, 6, 5, 4, 101
- POSTER AREA
- EXHIBITION AREA
- SPEAKERS PREVIEW ROOM
- CLOAKROOM
GENERAL INFORMATION

CONGRESS VENUE
Palazzo dei Congressi
Piazza Adua, 1 - 50100 Florence (Italy)
www.firenzefiera.it

WEBSITE
The FLORetina official website is www.floretina.com.

LANGUAGE
English is the official language. Simultaneous translations English/Italiano will be provided during main sessions in Auditorium, Room Verde and Room Onice.

REGISTRATION DESK HOURS
The Registration Desk will be opened as follows:
Thursday 6: 11:00 - 19:00
Friday 7: 07:30 - 19:00
Saturday 8: 07:30 - 19:00
Sunday 9: 08:00 - 13:30

EXHIBITION OPENING HOURS
The Exhibition will be opened as follows:
Thursday 6: 13:00 - 19:00
Friday 7: 08:00 - 19:00
Saturday 8: 08:00 - 19:00
Sunday 9: 08:00 - 13:00

CONGRESS NAME BADGE
Upon registration you will receive your name badge.
You are kindly requested to wear your badge during all sessions and events.
CERTIFICATES OF ATTENDANCE
Certificates of attendance will be sent by email after the meeting to all the registered participants that will attend the scientific sessions.

INTERNET ACCESS Wi-Fi
Internet access Wi-Fi is available for congress participants throughout the public areas.
In order to log in please use the following user name and password:
Username: floretina2019
Password: novartis

FLORetina APP
Install the FLORetina interactive mobile App to your smartphone and portable devices to access all the Congress information you could need during and after the Congress:
• See the overview of sessions, speakers and exhibitors;
• Create your own program for the event, including bookmarking the sessions you wish to attend;
• Vote during Live Surgery sessions;
• Receive real-time updates Download the FLORetina App now to enhance your congress experience!
Download available on iTunes and Google Play stores.

BREAKS
Lunch and refreshment breaks are included in the delegate fee and will be available as follows:

Thursday 6:
Refreshment break 16:00 - 16:30, Exhibition Area

Friday 7:
Refreshment station 09:00 - 12:00, Exhibition Area
Lunch* 13:00 - 14:00, Exhibition Area + Lunch Symposia Rooms Foyers
Refreshment break 16:15 - 16:45, Exhibition Area
Saturday 8:
- Refreshment station 09:00 - 12:00, Exhibition Area
- Lunch* 13:00 - 14:00, Exhibition Area + Lunch Symposia Rooms Foyers
- Refreshment break 16:15 - 16:40, Exhibition Area

Sunday 9:
- Refreshment station 09:00 - 12:00, Exhibition Area

*Tickets to collect the lunch box on Friday and Saturday are in your congress badge.
Please note that the lunch boxes will be distributed in the Exhibition Area and in the Foyers of the Lunch Symposia Rooms.

**CONGRESS DINNER**
The Congress Dinner will be hosted at **Salone de’ Cinquecento - Palazzo Vecchio**.
Friday 7, 20:30 - 23:30.
Admission is by tickets only and must be purchased in advance. Price € 85/person and subject to availability.

**CLOAKROOM**
A cloakroom is available for participants in the Level -1 close to the Exhibition Area and the Auditorium.

**SPEAKERS PREVIEW ROOM**
If you are speaking at the meeting, plan time to visit the Speakers Preview Room to review your presentation. This space will have an audio-visual tech on site.
The Speaker Preview Room will be located on the Level - 2 of the Palazzo Dei Congressi building, known as the PASSI PERDUTI.

This space is open during the following hours for speakers use:
- Thursday 6: 11:00 - 18:30
- Friday 7: 07:30 - 18:30
- Saturday 8: 07:30 - 18:30
- Sunday 9: 08:00 - 13:00
PowerPoint projection is available in all meeting rooms. For technical reasons speakers are not allowed to make presentations with their own laptops in the meeting rooms, but must load their presentation in the Speakers Preview Room.

**E.C.M. (ITALIAN ATTENDEES ONLY)**
Per il Congresso FLORetina 2019 non è previsto l’accreditamento residenziale. Per garantire la possibilità di acquisire i crediti formativi, sarà incluso nella quota d’iscrizione un programma di formazione a distanza (FAD) rivolto ai Medici, Infermieri, Ortottisti ed Assistenti in Oftalmologia.
La piattaforma FAD sarà disponibile a partire dal 31 Luglio 2019 fino al 31 dicembre 2019 all’indirizzo [www.floretina.com](http://www.floretina.com)

Ai fini dell’ottenimento dei crediti ECM è necessario:
- Collegarsi al sito ed inserire i propri dati personali e il proprio indirizzo email usando l’apposito form di registrazione;
- Validare la propria utenza attraverso un apposito link ricevuto all’indirizzo email fornito;
- Completare il percorso formativo e compilare tutti i questionari.

L’attestazione dei crediti è subordinata al superamento del questionario di valutazione dell’apprendimento con una percentuale uguale o superiore al 75% di risposte esatte (numero massimo di 5 tentativi a scalare).
L’attestato ECM, qualora ne ricorrano le condizioni, sarà scaricabile dall’apposita sezione “crediti ECM” del sito.

**MOBILE PHONES**
Please do not forget to turn your mobile phones to silent mode during sessions.

**NON-SMOKING POLICY**
The FLORetina Congress is a Non-Smoking event. Delegates are reminded that smoking in enclosed spaces is illegal in Italy.

**LIABILITY AND INSURANCE**
The Congress Secretariat and Organizers cannot accept liability for personal accidents or loss of or damage to private property of participants. Participants are advised to take out their own personal travel and health insurance for their trip.
SAFETY AND SECURITY
Please do not leave bags or suitcases unattended at any time, whether inside or outside the session halls.

FIRST AID
Should you require first aid assistance, please contact the registration desk or any uniformed member of the meeting staff.

CURRENCY
Euro (EUR)
All major credit cards (Visa, MasterCard, American Express) are accepted in most of the restaurants, shops etc.

ELECTRICITY
The electric current supplied is 220 V. Round, two-pin plug points are available, as elsewhere in Europe.
In case you have any devices from the USA or UK, please remember to bring a transformer/adapter.

BANKING
Most Florence banks open between 08:30 and 13:30 and 14:45 to 15:45 Monday to Friday. They are closed on weekends and public holidays and most of them have a cash dispenser and a currency exchange service.

TRANSPORTATION
• From the main train station: Firenze S. Maria Novella is the main station located right inside the city centre, in Piazza della Stazione, and a primary hub in Firenze’s public transport system. It hosts over 400 trains per day and is a major intersection point for many bus and taxi lines. The train station is located in front of the congress center.
  • From the airport: you can reach the congress center in tramvia, thanks to the new Leonardo Line T2 connecting the Airport to Piazza dell’Unità Italiana in 20 minutes. The “UNITA’” stop is in 400 mt far from the congress center. Ticket cost is € 1,50
  • Taxis: Taxis in Florence can be ordered by phone:
    +39 055 4242
    +39 055 4390
    or found at the official taxi stands. You cannot stop a taxi on the road.
• Bus: Florence has a comprehensive network of local bus routes. Most of them stop at the main railway station and therefore near to the convention venue. Bus tickets can be purchased at most coffee bars and kiosks. Fare is €1.20 multiple trips, valid up to 90 minutes.
• Car parking: There are several paying parking areas around the Congress venue.

USEFUL TELEPHONE NUMBERS IN FLORENCE
• Medical emergency: 118
• Fire emergency: 115
• Police: 113
• Florence airport - information: 055 3061300
• Florence airport - lost luggage: 055 3061302
• For international calls from Italy: 00 + country code + number
• For international calls to Italy: +39 + city code + number
• 24hour Pharmacies:
  - Santa Maria Novella Station
  - Via Calzaiuoli, 7 r
  - Piazza San Giovanni, 20
Install the **FLORetina interactive mobile APP** to your smartphone and portable devices to access all the Congress information you could need during and after the Congress:

- See the overview of sessions, speakers and exhibitors;
- Create your own program for the event, including bookmarking the sessions you wish to attend;
- Vote during plenary sessions;
- Receive real-time updates.

Download the FLORetina APP now to enhance your congress experience!

Download available on

![Google Play](https://play.google.com/store)  ![App Store](https://itunes.apple.com)

or point the camera of your device on the image beside

![QR Code](https://example.com/qrcode)

Requires an APP to scan the QRCode